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ABSTRACT 
 
EMILY O’BRIEN: Community Patterns of Acute Myocardial Infarction Therapy and 
Survival 
(Under the direction of Wayne Rosamond) 
 
Background. Reports from clinical trials and observational studies have 
characterized recent temporal trends and treatment patterns for AMI. However, have 
examined differences in patterns of treatment for patients presenting with ST elevation 
myocardial infarction (STEMI) and non-ST elevation myocardial infarction (NSTEMI). 
Additionally, reports on survival after AMI using propensity scores accounting for all 
medical therapies received during hospitalization are limited.  We examined 21-year 
trends in the use of 10 medical therapies and procedures by STEMI and NSTEMI 
classification and associated survival using propensity score (PS) adjustment in the 
ARIC Community Surveillance Study (ARIC).  
Methods. We analyzed data from 30986 definite or probable MIs between 1987 
and 2008 among all residents 35-74 years of age in the four geographically defined US 
communities of the ARIC Study. We used weighted multivariable Poisson regression to 
estimate average annual percent changes in medical therapy use over the study period. 
We then used 4 PS adjustment strategies to account for the non-randomized study 
design and the receipt of other medical therapies during hospitalization.  
Results. From 1987 – 2008, 6106 (19.7%) hospitalized events were classified as 
STEMI, and 20302 (65.5%) were classified as NSTEMI. Among STEMI patients, 
increases (%; 95% CI) were noted in the use of ACE inhibitors (6.4; 5.7, 7.2), non-aspirin 
anti-platelets (5.0; 4.0, 6.0), lipid-lowering medications (4.5; 3.1, 5.8), beta blockers (2.7; 
2.4, 3.0), aspirin (1.2; 1.0, 1.3), and heparin (0.8; 0.4, 1.3). Among NSTEMI patients, the
 iii 
use of ACE inhibitors (5.5; 5.0, 6.1), non-aspirin anti-platelets (3.7; 2.7, 4.7), lipid-
lowering medications (3.0; 1.9, 4.1), beta blockers (4.2; 3.9, 4.4) increased. Calcium 
channel blocker use decreased for both STEMI (-8.8%;-9.6,-8.0) and NSTEMI (-5.6; -
6.1,-5.1) patients over the study period. Medication and procedure use was associated 
with decreased risk of mortality at 30, 90, and 365 days after hospitalization for beta 
blockers, lipid lowering medications, aspirin, PCI, CABG and t-PA, even after adjustment 
for all medications received during hospitalization.  
Conclusion.  We found trends of increasing use of evidence-based medicine for 
both STEMI and NSTEMI patients over the past 22 years. Future research should 
examine the broader public health impact of increasing adherence to clinical therapy 
guidelines.
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I. INTRODUCTION 
 
 Coronary heart disease (CHD) is a major public health burden and the largest 
killer of American males and females. In 2005, CHD was responsible for 1 of every 5 
deaths in the United States.9 Acute myocardial infarction (MI) is the most common direct 
cause of mortality due to CHD. Each year, there are 610,000 new MIs and 325,000 
recurrent MIs.10 Approximately 16% of patients who experience an MI will die within one 
year of hospitalization. In addition to the substantial burden of mortality, MI is a major 
contributor to increasing health care expenditures. In 2004, hospitalized MI resulted in 
approximately $31 billion in inpatient charges. In response to rising costs, the American 
Heart Association (AHA) recently published recommendations for identifying the most 
cost-effective treatments for MI as a major priority.11 A wealth of data from clinical trials 
and observational studies has led to major advancements in medical care for 
hospitalized MI. Analyses of National Health and Nutrition Examination Survey 
(NHANES) data collected between 1980 and 2000 suggest that both in-hospital 
treatment for MI and secondary preventive therapies have substantially contributed to 
the decreasing MI death rates.12 However, the abundance of data on medical treatment 
for MI has done as much to set the standard of care as it has to diversify it. Furthermore, 
while there may be substantial support for the efficacy of various medications and 
procedures as observed in randomized clinical trials (RCT), clinical trial results do not 
always translate to community-based settings. Additionally, evidence-based treatments 
may take time to disseminate into clinical practice, and the use of these treatments may 
vary by provider and geographical area. Monitoring both the patterns of use and 
outcomes of treated patients as evidence-based therapies disseminate into the 
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community is important in shaping future clinical decisions and further reducing mortality 
due to CHD.  
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II. REVIEW OF THE LITERATURE  
II. A. Temporal Trends in Hospitalized MI Event Rates & Medical Therapy for MI 
While CHD remains a public health burden in terms of absolute number of events, 
death rates attributable to CHD have declined in the US since the late 1960s.13,14 These 
declines are likely the result of a combination of factors, including changing lifestyle 
practices and advances in medical treatment approaches.15-21 A study examining the 
decline in death due to CHD between 1980-2000 found that nearly half the decrease in 
CHD mortality was attributable to medical advancements over the past two decades12. In 
addition to changing use of evidence-based medical therapies, recent evidence from 
several large databases has documented shifts in the demographic makeup, length of 
stay, and in-hospital management of acute MI patients over the past 30 years.22-25 Floyd 
(2009) assessed changes in demographic patterns of 8898 hospitalized acute MI 
patients in the Worcester Heart Attack Study from 1975 – 2008. Compared with patients 
hospitalized in 1975, patients in recent years were more likely to be older, female, 
obese, and have a prior history of diabetes, hypertension, stroke, and heart failure.13 
Investigators also reported a marked decrease in length of hospital stay, with the 
average length of stay of 17 days in the mid-1970’s decreasing to approximately 5 days 
in 2005. Similar changes in baseline characteristics were documented in the National 
Registry of Myocardial Infarction (NRMI).8 As the population ages and the burden of 
comorbidities increases, in-hospital management of MI becomes more complex.  
Furthermore, the process of updating guidelines for clinical practice has accelerated, 
and financial pressures and policy initiatives aimed at utilizing the most cost-effective, 
evidence-based treatments are continually increasing.26 Understanding patterns of 
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Figure 2.1. Trends in Medication Use at 
Discharge (1990-1999) in the NRMI. 8  
implementation and observed utility of emerging therapies in the dynamic clinical 
environment is integral to effectively improving outcomes for MI patients.  
II.A.i  Trends in Medications and Procedures for Myocardial Infarction 
The availability of medical therapies for in-hospital management of MI is increasing 
each year.27 As guidelines are published and revised, more effective therapies become 
available, and additional data from clinical trials and observational studies confirms their 
efficacy, rates of medication and procedure use in clinical practice change. Reports from 
large databases have enhanced our understanding of evolving patterns of treatment for 
MI.  
II.A.i.a Trends in Medications 
Patterns of medication use during in-hospital treatment for MI and at hospital 
discharge have undergone significant changes over the past decades. Data from the 
Minnesota Heart Survey documented major 
changes in age and severity-adjusted 
use of evidence-based medications 
from 1985 – 1995. Aspirin, heparin, 
beta-blocker, and angiotensin-
converting enzyme (ACE) inhibitor use 
all increased markedly throughout the 
study period. Decreases were reported 
in utilization rates of both calcium 
channel  blockers (CCB) and 
lidocaine.28  
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Figure 2.2. Trends in Reperfusion Therapy    
(1990-1999) in the NRMI. 8  
Temporal trends in treatment and outcome for myocardial infarction were analyzed 
using data from 1.5 million patients in the National Registry of Myocardial Infarction 1,2, 
and 3, which currently enrolls patients from over one quarter of acute care hospitals in 
the US.8 The use of beta-blockers, aspirin, ACE inhibitors, and non-aspirin anti-platelets 
all increased during the first 24 hours of hospitalization, as well at hospital discharge. In-
hospital mortality also decreased over the study period (11.2% to 9.4%). The Worcester 
Heart Attack Study documented similar declines in CCB and increases in ACE inhibitors 
and beta-blockers.29 However, the results of these studies have several important 
limitations. The Worcester Heart Attack Study was limited to white participants, so trend 
estimates may not be generalizable to racially heterogeneous populations. NRMI is a 
large, nationwide registry, but is likely more reflective of practice patterns of larger 
centers.30 Additionally, there is no independent validation of registry data. Finally, NRMI 
does not collect data on follow-up beyond hospital discharge, limiting the ability to make 
conclusions about outcomes after hospitalization. 
II.A.i.b  Trends in Revascularization Procedures 
The development of revascularization procedures for use during hospitalization 
represents one of the most significant scientific advancements in the treatment of MI. A 
number of reports on revascularization 
trends suggest that use of fibrinolytics and 
coronary artery bypass grafting (CABG) 
for hospitalized acute MI is decreasing, 
while use of PCI, especially with stents, 
is increasing. Results from the NRMI 
report that during 1990-1999, use of IV 
thrombolytics declined (34.3% to 
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Figure 2.3. Temporal trends in in-hospital mortality 
by revascularization procedure in the NHDS (1990-
2004)7. 
20.8%) but rates of primary angioplasty increased (2.4% to 7.3%).8  In an analysis of 
therapeutic coronary procedures performed between 1990 and 2004 in Olmsted County, 
Minnesota, investigators reported a sustained increase in percutaneous coronary 
interventions (PCI) (69%; 95% CI: 43% to 101%), as well as a stabilization, followed by a 
decline (-33%; 95% CI:  -16% to -47%) in CABG.31 PCI use increased most dramatically 
in the elderly and in women. Similar patterns were reported in MI patients in Washington 
State.22  
Recent data from the Acute Care Tracker (ACTracker) database, which contains 
administrative records on approximately 6 million discharges per year from 458 hospitals 
in the US, suggest that total revascularization procedures may be declining. Overall 
adjusted coronary revascularization procedure rates (per 100000) declined from 382 in 
2002 to 358 in 2005. Rates of PCI increased slightly during the study period (264  in 
2002 to 267 in 2005), while rates of CABG decreased (121 in 2002 to 94 in 2005).32 
However, because ACTracker utilizes administrative data, specificity is likely to be 
higher than sensitivity, increasing the potential for undercounting of procedures. Similar 
results were documented in the NRMI, which indicated a decrease in overall use of 
reperfusion (either PCI or thrombolytics), from 36.8% in 1990 to 28.1% in 1999. There 
was a simultaneous decrease in the percentage of patients presenting with Q-wave 
infarction or left bundle branch block (LBBB) within 12 hours of symptom onset (36.4% in 
1994 to 27.1% in 1999). Among these 
patients, the use of PCI or 
thrombolytics increased slightly 
(68.8% to 70%), suggesting that 
declines in overall use of reperfusion 
may be due to decreases in the proportion of eligible patients (patients presenting with 
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Q-wave infarction or LBBB within 12 hours) rather than increasing failure to treat eligible 
patients. Thrombolytic use in this population increased from 1985-1990 but remained 
stable thereafter. Rates of CABG doubled in men throughout the study period but 
remained stable in women.28 
Investigators recently examined NHDS data (1990-2004) for trends in PCI and 
CABG use as well as in-hospital mortality by reperfusion strategy.7  Rates of PCI use 
(per 10 000 patients) increased from 37.2 patients in 1990-1992 to 59.2 for patients in 
2002-2004, a 58% increase. Rates of CABG use initially increased from 34.1 in 1990-
1992 to 39.1 in 1996-1998 before decreasing to 25.2 in 2002- 2004. Both CABG and 
PCI discharge rates were substantially higher for males than for females throughout the 
study period, with trends in use similar for both males and females. In hospital-mortality 
rates (deaths/100 discharges) declined from 4.3 to 3.5 for CABG patients during the 15 
year interval, but remained stable for patients undergoing PCI. The greatest decrease in 
mortality rates for CABG patients was seen in women.  
 While most trend analyses have reported increases in the rate of PCI use over 
time, the specific type of PCI performed has also changed as new medical technologies, 
such as stents, have become available. The first bare-metal stent (BMS) was approved 
for use in the U.S. in 1994, and their use quickly rose throughout the 1990’s. A cross-
sectional study of Medicare patients from 1993-2001, Lucas (2006) observed marked 
growth in PCI use (6 to 12 per 1000 beneficiaries),33 with a 7-fold increase in use of 
stents since 1995. As the use of stents increased, the rates of repeat revascularization 
procedures during the subsequent 6 months decreased. Although the development of 
BMS improved the safety of PCI, restenosis still occurred in a substantial proportion of 
patients undergoing the procedure. The approval of drug-eluting stents (DES) in 2003 
has helped to alleviate this problem,34 but there is still some concern about the 
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association between DES and late-stent thrombosis, with several recent studies 
reporting increased risk of late-stent thrombosis in patients treated with DES.35-37 
Understanding changes in practice patterns as new revascularization procedures are 
developed and existing technologies are improved can inform efforts to increase 
utilization of the most cost-effective and beneficial therapies for MI.  
Although these and other analyses have helped to characterize temporal patterns of 
treatment for MI, there are several important limitations to the findings of these studies 
that are worth noting. First, many trend analyses are limited to short-term (<5 years) of 
data. Because innovative medical therapies may take years to disseminate into clinical 
practice, a longer window of time provides a more comprehensive perspective of the 
temporal patterns of treatment. Second, several were limited to one state or geographic 
area, limiting the generalizability to other regions of the country. Finally, many of these 
studies have used a naïve linear trend test to examine the changes in medication use 
over time. While useful in gaining a broad understanding of changes in treatment use, 
this test does not provide a detailed picture of the dynamic nature of medical innovation, 
as the use of many medical therapies follow non-linear trends. The proposed study will 
provide an important perspective on trends in medication and procedure use in 4 U.S. 
communities over 20 years, with specific aims of understanding any departure from 
linearity in trend estimation. For more details on the methodology of the current study, 
please see Section III. 
II. B. In-Hospital Interventions 
A wealth of data from clinical trials and observational studies has contributed to 
improvements in hospitalized MI outcomes over the past 30 years. Analyses of survival 
associated with a number of pharmacological interventions (aspirin, beta-blockers, ACE-
inhibitors, calcium-channel blockers, heparin, non-aspirin anti-platelets, and statins) and 
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reperfusion strategies (fibrinolytic therapy, PCI, and CABG) have informed the process 
medical management for MI and contributed to improved patient outcomes after hospital 
discharge.  
 II. B. i. Pharmacological Treatment for MI 
  II. B. i.a  Anti-platelets 
   II. B. i.a.1  Aspirin 
Aspirin has been used to treat a variety of anti-inflammatory conditions since the late 
1890’s, but its anti-platelet properties were not discovered until the 1960’s38. The clinical 
utility of aspirin for patients with MI lies in its ability to induce a rapid anti-thrombotic 
effect by inhibiting production of thromboxane A2, a cyclic prostanoid that increases 
platelet aggregation. The benefits of aspirin use for acute ST-elevation myocardial 
infarction (STEMI) were unequivocally demonstrated in the Second International Study 
of Infarct Survival (ISIS-2).39 Patients were randomized to receive daily aspirin, IV 
streptokinase, both, or neither. Investigators reported absolute risk difference in 35-day 
mortality of 2.4% (relative risk reduction 23%) for aspirin alone, and an absolute risk 
difference of 5.2% (RRR of 42%) for aspirin combined with streptokinase. 
Aspirin use in MI patients has been associated with a reduced risk of composite 
endpoints (death or reinfarction),40,41 and reduced rates of coronary reocclusion and  
recurrent ischemic events after administration of streptokinase or alteplase.42 In a 
collaborative meta-analysis of 287 studies involving 135,000 patients in comparisons of 
antiplatelet therapy versus control and 77,000 comparing different anti-platelet regimens, 
aspirin reduced non-fatal MI by 1/3, non-fatal stroke by ¼, and vascular mortality by 
1/6.43 Because of data from these and other studies, the AHA has issued Class1A 
recommendations that aspirin should be administered to patients presenting with STEMI 
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Figure 2.4. Coagulation cascade and thrombin 
formation during acute MI.  
4
 
within the first 24 hours of hospitalization and at hospital discharge.44 In patients with 
contraindications to aspirin, Warfarin may be used as an anti-thrombotic agent. A meta-
analysis of warfarin use in CAD patients found that warfarin (high or moderate intensity) 
plus aspirin seemed to confer greater benefit than aspirin alone.45 However, the 
translation of these results to community-based practice has not been well-documented.  
   II. B. i.a.2 Non-aspirin anti-platelets 
Platelet aggregation in MI is a complex process, operating through a number of 
distinct pathways and cascades. The aggregation process is inhibited only in part by 
aspirin, which acts primarily by 
blocking the thromboxane-
mediated pathway (Figure 2.4). 
Because of this, new anti-
platelet drugs that target other 
aggregation pathways, 
including Clopidogrel and 
glycoprotein IIa/IIIb inhibitors, 
have been increasingly utilized in the management of MI (Figure 2.1). Several recent 
clinical trials support the use of clopidogrel in addition to standard in-hospital therapy for 
MI. In the COMMIT trial, 45800 patients were randomly allocated clopidogrel or placebo 
in addition to a daily aspirin regimen. Investigators reported a 9% reduction in death, 
reinfarction, or stroke in STEMI patients.46  Evidence from the CLARITY-TIMI 28 trial 
suggests that addition of Clopidogrel to a regimen of aspirin, heparin, and thrombolytics 
reduced the risk of a composite endpoint of TIMI grade 0 or 1 flow, death or 
reinfarction.47 However, the treatment and control groups did not differ in rates of death 
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or reinfarction, and it is not clear whether greater TIMI flow translates to mortality 
benefits.48  
Currently, little evidence exists supporting the use of glycoprotein IIb/IIIa inhibitors as 
the sole means of reperfusion, as they do not appear to restore TIMI 3 flow in the 
majority of patients.49 However, the combination of fibrinolytics (half-dose reteplase or 
tenecteplase) and abciximab is currently recommended for prevention of reinfarction and 
other complications of STEMI in patients with anterior MI, who are younger than 75 
years, and who have no major risk factors for bleeding. In two clinical trials of 
combination reperfusion, and ASSENT, combination therapy resulted in reduced rates of 
MI and other complications (GUSTO-V)50 and reduced reinfarction and refractory 
ischemia (ASSENT).51 However, the prevention of reinfarction did not translate into a 
survival benefit at either 30 days or 1 year. In a meta-analysis of 11 trials involving 
27115 patients, de Luca (2005) reported reductions in short- and long-term PCI patients, 
but not in patients receiving fibrinolytic therapy.52 In the Atherosclerosis Risk In 
Communities (ARIC) study, non-aspirin anti-platelet drugs are classified into a one 
group, so these therapies will be evaluated as a single treatment group.  For further 
discussion on fibrinolytics and ancillary therapy, please see Section 1.5.2.1.2.  
  II. B. i.b  Beta-blockers 
The American Heart Association class 1A recommendations for oral beta-blocker 
(BB) therapy suggest that BBs should be promptly administered to non-contraindicated 
patients, irrespective of fibrinolytic therapy or PCI. When administered within several 
hours of STEMI onset, BBs reduce systemic arterial pressure, heart rate, and myocardial 
contractility, thereby reducing oxygen demand in the myocardium. BBs have been 
shown favorably influence infarct size in subjects not receiving fibrinolytic therapy, and to 
reduce the rate of reinfarction in subjects receiving fibrinolytic therapy.  
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Mortality benefits associated with beta-blocker therapy prior to the fibrinolytic era 
have been documented. In an analysis of 16000 MI patients with suspected MI, 
immediate atenolol followed by oral atenolol resulted in a 7-day mortality reduction 
compared to those not receiving atenolol (4.3% vs. 3.7%).53 Results from the MIAMI trial, 
in which 5700 acute MI patients were randomly assigned to metoprolol or placebo, 
report significantly lower 15-day mortality in patients receiving metaprolol (4.3%) than in 
those receiving placebo (4.7%).54 However, the mortality benefit associated with the 
routine use of IV-BB early in the course of hospitalization has been challenged by 
several subsequent studies. In a post-hoc analysis of atenolol use in the GUSTO-I trial, 
a significant mortality benefit was not observed in patients.55 Additionally, a systematic 
review of early BB therapy did not document a significant mortality reduction in HF 
patients.56 Finally, results from a large clinical trial conducted in China (n=45,852) did not 
report lower incidence of a composite endpoint of death, reinfarction, or cardiac arrest in 
patients receiving early metoprolol compared to those receiving placebo.57 The utility of 
BB therapy as an immediate, early therapy for MI is unclear. 
Heart failure patients and patients in cardiogenic shock represent a special 
population of patients with regard to the use of beta-blocker therapy. Data from two 
recent trials underscore the risk of early beta blocker administration to patients with 
severe heart failure or cardiogenic shock.58,59 As a result, the AHA recommends oral BB 
use during the first two days of STEMI hospitalization for hypertensive patients not at 
increased risk for cardiogenic shock.44 Additionally, the presence of moderate LV failure 
early in the course of STEMI precludes the use of early IV beta-blockade until the heart 
failure has been compensated. However, long-term BB use is strongly recommended for 
these patients once HF has compensated and/or shock has stabilized.  
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As the use of PCI in MI increases, examinations of outcomes associated with various 
medical therapies in patients who are also undergoing angioplasty are becoming 
increasingly important. The relationship between post-discharge outcomes in patients 
receiving both beta-blocker therapy and PCI has not been well-documented. To date, no 
randomized trials examining the use of BB therapy and PCI have been conducted. A 
pooled study of 2442 patients who underwent successful primary PCI in 4 clinical trials 
compared rates of death and adverse cardiac events at 6 months reported lower 6 
month mortality among PCI patients receiving BB therapy than in those who did not 
(OR=0.43; 0.26, 0.73), with the greatest benefit observed in patients with a low EF or 
multi-vessel CAD.60 However, data from the CAPRICORN trial indicate a benefit of BB 
therapy in patients with transient or sustained post-infarction LV dysfunction in both PCI 
and fibrinolytic patients.61 Nevertheless, these results have not been replicated in 
community-based settings. The current study will examine survival associated with BB 
therapy within strata of revascularization to determine what, if any, increases in survival 
are associated with BB use in PCI patients.  
  II. B. i. c  Calcium-channel blockers 
Calcium channel blockers (CCBs) were the most commonly prescribed anti-
hypertensive drug in 1995.62 CCBs block voltage-gated calcium channels in blood 
vessels and cardiac muscle, thereby reducing muscle contraction, increasing 
vasodilation, and decreasing blood pressure. However, the effect of early CCB use in 
hospitalized MI on mortality has been called into question. In an analysis of 19000 
patients in 28 randomized trials, investigators did find evidence of a beneficial effect of 
CCB on mortality (OR = 1.06, 0.96 – 1.18).63 Similar results were observed among trials 
involving the acute phase and among longer-term trials following patients up to 2 
years.64-67 In a clinical review of pharmacological strategies secondary prevention for 
 
 
14 
acute MI, investigators concluded that immediate-release Nifedipine does not reduce 
mortality or reinfarction in MI patients, regardless of demographic or clinical 
characteristics, and whether the patient also received fibrinolytic therapy, and may be 
harmful in patients who are hypotensive or tachycardic.68  
While overall results from a number of RCTS of CCBs have not reported mortality 
benefits, immediate-release verapamil given several days after acute MI in patients with 
preserved LV function who were not eligible for beta blockers was found to reduce 
incidence of a composite endpoint of reinfarction or death.69-71 Results from two clinical 
trials suggest that patients with non-Q-wave MI or with Q-wave infarction and preserved 
LV function may benefit from diltiazem therapy; however, 53% of placebo patients and 
55% of treatment patients in one of these trials also received beta-blocker therapy, 
which may have confounded results.70,72 Results from the more recent INTERCEPT trial 
did not report decreases in cumulative incidence on cardiac death, but did report 
reductions in non-fatal cardiac events, such as the need for myocardial 
revascularization.73  
The ALLHAT trial randomized high-risk hypertensive patients to a CCB, an ACE 
inhibitor, an alpha-blocker, or a diuretic.74 The primary outcome (fatal CHD or non-fatal 
MI) occurred at similar rates in all treatment groups. However, the CCB treatment arm 
was associated with higher 5-year systolic BP and rates of HF than the diuretic 
treatment arm, leading investigators to conclude that thiazide-type diuretics are less 
expensive as well as superior in preventing 1 or more major forms of CVD than CCBs.  
The additional benefits offered by CCBs to MI patients in the era of aspirin and beta-
blockade are unclear.  
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  II. B. i. d IV heparin 
Intravenous (IV) heparin has been used in management of acute MI for nearly 40 
years.75 The use of fibrinolytics results in activation of the coagulation cascade, which 
leads to production of thrombin and fibrin strand deposition. Because of this, ancillary 
therapy used specifically to inhibit this cascade in patients undergoing reperfusion is 
integral in preventing re-infarction.76 IV heparin functions as an antithrombotic that 
inhibits the coagulation cascade by inactivating thrombin and other proteases involved in 
blood clotting. However, the marginal utility of IV heparin in conjunction with select 
reperfusion therapies may vary by the type of fibrinolytic used. Non-specific fibrinolytic 
agents (streptokinase, anistreplase, and urokinase) are themselves anti-coagulants, and 
thus, at least conceptually, diminish the rationale for concomitant anticoagulation with IV 
heparin. However, streptokinase specifically has been shown to induce plasmin-
mediated thrombin activity, which increases procoagulant potential and has been cited 
as rationale for concomitant use of IV heparin.77  
In ISIS-3, 41,000 patients receiving streptokinase, anistreplase, or alteplase were 
randomly assigned to heparin or no routine heparin. A small reduction in mortality was 
observed during the heparin administration period (4 to 5 lives saved per 1000 treated), 
after which the number of lives saved decreased to 2 to 3 per 1000 and was no longer 
statistically significant.78 Similar reductions in mortality associated with heparin use were 
observed in a meta-analysis of 68000 patients treated with streptokinase with or without 
heparin.79 In 2004, the AHA published Class IC recommendations that PCI and CABG 
patients should receive UFH, and Class IB recommendations that IV heparin should be 
given to patients treated with non-selective fibrinolytic agents who experience large or 
anterior MI, atrial fibrillation, previous embolus, or known LV thrombus.44 The magnitude 
of additional benefit conferred by heparin use in the fibrinolytic era is not clear. 
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  II. B. i. e  ACE inhibitors 
In an overview of data from 4 randomized trials (CONSENSUS-II, CCS, ISIS, SMILE) 
comprising 98496 patients  with ACE inhibitor therapy started in acute phase (0 to 36 
hours) & continued for 4 to 6 weeks was associated with a decrease in 30-day mortality 
(7.1% in treatment group versus 7.6% in control group).80 This mortality reduction 
translated to an absolute benefit of 4.6 fewer deaths per 1000 patients. In the ISIS-4 
trial, the largest relative benefit was seen in days 0-1 (44 fewer deaths compared to 
controls) and in days 2-7 (37 fewer deaths), demonstrating the importance of early 
therapy.81 The mortality benefit of ACE inhibitors appears to be particularly large in high-
risk patients (Killip class 2 or 3, heart rate >=100 bpm on admission), and in patients 55 
to 74 years of age, with anterior infarct, or presenting with pulse rate of 80 bmp or 
higher. For patients contraindicated to ACE inhibitors, angiotensin receptor blockers 
(ARBs) may be administered. ARBs have shown similar mortality benefits to ACE-
inhibitors in MI patients who also have residual LV dysfunction.82 In 2006, the ACC/AHA 
added ARBs to the performance measure for ACE-inhibitors in LVSD patients, indicating 
that ARBs were an “effective alternative therapy’ for patients with LVSD and 
contraindications to ACE-inhibitors.83 The ARIC study collects data on ACE-inhibitors 
and ARBs in a single question (“ACE or Angiotensin II inhibitors”). Thus, ARBs and 
ACE-inhibitors will be assessed as a single medication group.   
  II. B. i. f  Statins 
Statin use, both during the initial MI hospitalization and after discharge, reduces the 
risk of death in patients with coronary artery disease. The widespread use of statins in 
patients at risk for cardiovascular events is a recent development. Results from the first 
major study documenting a beneficial effect of statins in patients at risk for CHD were 
published in 1994.84 A 42% reduction in CHD mortality was documented in 4444 patients 
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with moderate hypercholesterolemia the Scandinavian Simvastatin Survival Study. 
Interestingly, similar mortality reductions were reported among groups with the lowest 
quartile and the highest quartile LDL-C, suggesting that Statins may be effective in 
reducing CHD mortality even in patients with mild to moderate hypercholesterolemia. 
In the CARE Trial, 4159 patients with a history of MI and mean cholesterol values 
similar to those of the U.S. population were randomly assigned to pravastatin or placebo. 
Investigators reported a 24% relative risk reduction in adverse events (fatal CHD and 
non-fatal MI) over a period of 5 years.85 Similar relative risk reductions were reported in 
the lipid study, which was stopped prematurely because of the observed efficacy of 
prevastatin in reduction of CHD mortality, total mortality, and stroke.86 Smaller reductions 
in mortality were reported in the Heart Protection Study, which documented the largest 
decreases in total mortality in women, the elderly, and subjects with a baseline LDL-C of 
<100 mg.dl.87 
While early trials of statin therapy have focused on patients initiating statin treatment 
regimens 4 to 6 months after hospital discharge, newer studies have evaluated the 
benefits of statin use during the acute phase of MI. The Lipid-Coronary Artery Disease 
Trial randomized 126 patients with CAD to early pravastatin treatment or usual care. 
Compared to the usual care group, patients treated with pravastatin had fewer clinical 
events 2 years after discharge.88 In the MIRACL trial, 3086 patients admitted for ACS 
were randomized to atorvastatin or placebo within 4 days of admission. The risk of a 
composite endpoint of death, non-fatal MI, resuscitated cardiac arrest, or recurrent 
severe ischemia was significantly lower in the atorvastatin patients (14.8%) than in the 
placebo patients (17.4%).89 In a prospective cohort study of 20000 ACS patients in 
Sweden, Stenestrand, et al (2001) documented a 25% reduction in 1-year mortality 
among patients treated with statins.90 
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Results from some trials support the use of intensive statin therapy over moderate or 
conservative statin therapy. The PROVE-IT (TIMI-22) trial randomized 4162 patients to 
intensive (80 mg/dl) vs. moderate (40 mg/dl) therapy within 10 days of hospital 
admission. Reductions were documented in 2-year risk of a composite endpoint (all-
cause mortality, recurrent MI, and stroke) in patients undergoing intensive therapy 
(22.4%) compared to those undergoing moderate therapy (26.3%).91 Favorable trends in 
all-cause mortality trial and intensive statin use were also documented in the A to Z trial, 
but these estimates did not reach statistical significance.92  
Statin use is contraindicated in patients with liver disease and patients who are 
pregnant. Despite strong support for statin use from national guidelines, low number of 
contraindications, and rarity of serious side effects, actual use of statins after MI varies, 
with 20% of patients discontinuing use within a month after hospital discharge93 and 30% 
discontinuing use after 1 year.94,95 Patterns of statin adherence and their resultant impact 
on mortality will be explored in the proposed project. For more information on 
classification of statin adherence, please see section 1.8.   
 II. B. ii Reperfusion Procedures  
         II. B. ii. a  Fibrinolytics 
Fibrinolytics confer a mortality benefit to STEMI patients by reducing infarct size, 
thereby salvaging healthy myocardium; favorably influencing infarct healing and 
myocardial remodeling; and reducing the potential for ventricular arrhythmia.96 However, 
these effects appear to be time-dependent, with most RCTs demonstrating benefits only 
when fibrinolytics are administered within 12 hours. The AHA Class IA recommendation 
regarding fibrinolytics suggests that, in non-contraindicated patients, fibrinolytics should 
be administered to STEMI patients within 12 hours of symptom onset who have ST 
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elevation greater than 0.1 mV in at least 2 contiguous precordial leads or 2 adjacent limb 
leads. 
The mortality benefit of fibrinolytics in MI patients has been well-established in a 
number of large clinical trials, inluding the GISSI, ISIS-2, the AIMS study, and the 
ASSET trial.39,97-99 In a 1994 overview of 58,600 patients in 9 clinical trials of fibrinolytic 
therapy vs. control, investigators found a 21% relative reduction in 35-day mortality in 
STEMI patients.100 The greatest mortality benefit was observed within the first hour of 
symptom onset, with a decrease in benefit of 1.6 per 1000 patients for every one hour 
delay.  The mortality reduction associated with fibrinolytic therapy has been observed 
regardless of important covariates (including sex, history of diabetes, BP, heart rate 
[<180 mm HG]), or history of previous MI.  
      II. B. ii. a  Types of fibrinolytic therapy 
Data from the Gusto-I101 and Gusto-III102 trials suggest that accelerated alteplase and 
reteplase with IV heparin may be more effective in achieving early reperfusion over 
streptokinase. However, these therapies are more expensive and confer slightly greater 
risk of ICH.  The ARIC surveillance study collects data on a single question documenting 
whether the patient received streptokinase, urokinase, anistreplase, APSAC, or TPA 
reperfusion.  
       II. B. ii. b  Combination therapy  
While the development fibrinolytic therapy has undoubtedly improved MI patient 
outcomes, it has 3 important physiological caveats worth noting: 1) the targeted 
thrombus can break apart into smaller pieces, resulting in microembolisation; 2) the 
fibrinolytic targets only the fibrin-rich part of the thrombus, leaving the platelet-rich 
portion unaffected; and 3) fibrinolysis leads to increased free thrombin and activates 
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platelet aggregation. Because of this, fibrinolytics are used in conjunction with an 
aggressive anti-platelet regimen.  
Aspirin is a weak anti-platelet agent, inhibiting only one of several platelet 
aggregation pathways. Thus, non-aspiring anti-platelets are often used, specifically 
those that inhibit the platelet glycoprotein IIb/IIIa. The use of GP IIB/IIIA inhibitors in 
acute MI is supported by evidence from a number of clinical trials indicating more 
complete reperfusion103-106 and shorter times to ST-segment resolution107,108 than 
fibrinolytic therapy alone.  
Because thrombin is released from the thrombus during fibrinolytic therapy, 
antithrombin agents such as heparin may be administered to patients receiving 
pharmacologic reperfusion. However, reports from several large trials did not document 
significant reductions in 30-day mortality or reinfarction among patients given heparin 
compared to those given placebo.78,109 Additionally, investigators reported increases in 
major bleeding complications. Despite the lack of reported mortality benefits, 
unfractionated heparin is still commonly given to patients receiving streptokinase.  
       II. B. ii. b  Percutaneous Coronary Intervention (PCI) 
Percutaneous Coronary Intervention (PCI) is a highly-effective mechanical 
revascularization procedure that has been used in hospitalized MI patients in the US for 
25 years. PCI involves the inflation of a balloon catheter at the site of a thrombotic 
occlusion in an infarct-related artery, with or without the placement of a stent. When 
performed in a timely fashion in eligible patients, PCI results in reestablished TIMI-2 flow 
range from 70%-90%.110-112 
PCI is especially useful in patients who are at high risk for reinfarction,113 for whom 
fibrinolysis is not successful,114,115 and for patients who are contraindicated to 
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fibrinolysis.116 However, PCI administration is dependent on both the availability of 
skilled staff and the time window since symptom onset. The AHA recommends that, if 
immediately available, primary PCI should be performed in a timely fashion (within 90 
minutes of symptom onset) by persons who are skilled in the procedure (perform more 
than 75 PCI procedures per year) in a supported laboratory environment (performs more 
than 200 PCI procedures per year).  If the expected additional time needed for PCI 
administration compared to fibrinolytic administration is greater than 1 hour, fibrinolytics 
are preferred. However, if the symptom duration on presentation is more than 3 hours, 
PCI should be performed.44  
Because so few facilities are equipped with the resources necessary to successfully 
administer PCI, patients presenting to non-PCI capable facilities are often transferred to 
PCI-capable facilities for the procedure. It is still unclear whether the increased delay 
associated with transfer to a PCI-capable facility is merited by the relative benefit of PCI. 
Results from the DANAMI-2 trial suggest that patients who present to centers without 
cardiology capabilities had better outcomes with transfer for PCI than with fibrinolytic 
treatment at the presenting hospital, but these results have not yet been replicated.117 
   II. B. ii. b. 1  Stents 
Stent use for MI has increased markedly in the past decade following the publication 
of results from several clinical trials. In a 1999 study by Grines and colleagues, 900 MI 
patients were randomly assigned to angioplasty with stenting or angioplasty alone. 
Investigators reported several benefits associated with stenting, including decreased 
rates of prevalence of angina and lower occurrence of a combined endpoint of death, 
reinfarction, disabling stroke, or need for target-vessel revascularization. However, 
according to study investigators, the decrease in the combined endpoint was “due 
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entirely to the decreased need for target-vessel revascularization”, and mortality rates 
between the two groups were not statistically different.110   
Results from another, smaller clinical trial also report better event-free survival at 
one-year in a systematic stenting group (80.2%) than in a conventional angioplasty 
group (71.8%).118 This difference also appeared to be driven by a decreased need for 
revascularization. Whether the increase in event-free survival associated with stent use 
that has previously been reported extends to mortality benefits at one year in unclear. 
   II. B. ii. b. 2  Facilitated PCI 
Recent trials have investigated the association between mortality and “facilitated 
PCI”, or PCI performed after fibrinolytics have been administered. In ASSENT-4, a trial 
of 1667 patients receiving full-dose tenecteplase and PCI versus primary PCI alone,119 
patients who were received fibrinolytics prior to PCI experienced increased rates of in-
hospital death compared to those undergoing PCI alone. The FINESSE trial randomized 
2452 patients to reduced-dose fibrinolytics plus abciximab alone followed by PCI or 
placebo. Results from FINESSE found similar rates of a composite endpoint in patients 
receiving abciximab and reteplase prior to PCI, abciximab alone before PCI, and 
abciximab alone at the time of PCI.120 Because these results were reported after the 
majority of the study period, we do not expect a large number of patients to have 
undergone both PCI and fibrinolytics; however, if the number of patients undergoing 
facilitated PCI is substantial and power considerations allow, we will analyze patients 
receiving both PCI and fibrinolytics as a distinct treatment group.  
      II. B. ii. c  Comparison of PCI and Fibrinolytics 
Evidence from clinical trials suggests that for facilities that have PCI capabilities, PCI 
may be superior to fibrinolysis in preventing adverse outcomes including death, recurrent 
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MI, or stroke. In a meta-analysis 23 clinical trials comparing PCI to thrombolytics (RR; 
95% CI), patients undergoing PCI experienced lower rates of short-term mortality (0.70; 
0.58-0.85), less nonfatal reinfarction (0.35; 0.27-0.45), and less hemorrhagic stroke 
(0.05; 0.006-0.35) than those receiving thrombolytic therapy. However, PCI patients did 
experience slightly increased rates of major bleeding. (1.3; 1.02-1.65).121  
Much of the benefit seen in PCI patients appears to be driven by reduced rates of 
nonfatal recurrent MI. The DANAMI-2 study randomly assigned 1572 patients with >0.4 
mV of ST elevation in 2 contiguous leads who arrived to the hospital within 12 hours of 
symptom onset to PCI or accelerated alteplase. A composite endpoint of death, 
reinfarction, or stroke within 30 days was documented in 8.5% of PCI patients and 
14.2% of fibrinolytic patients.117 However, the results of this trial have been questioned 
due to concerns about study methodology, including the use of a combined outcome, the 
exclusion of diabetics and other high-risk patients, and the low proportion of screened 
patients that were included in the trial.122  
Several important caveats regarding the use of PCI in MI are worth noting. First, the 
mortality benefit of PCI over fibrinolytics decreases as time delay increases, and 
fibrinolytics can be administered more quickly than PCI.123 Second, it is estimated that 
20% of hospitals nationwide have catheterization labs, and even fewer have the ability to 
administer primary PCI. The benefit of PCI over fibrinolytics may also vary by hospital 
size. Lower mortality rates after PCI compared to fibrinolytics have been documented for 
intermediate and high volume centers, but not for lower volume hospitals.124 In an 
analysis of NRMI data, investigators documented an inverse relationship between PCI 
procedure volume and mortality rates for STEMI patients; this same association was not 
documented for fibrinolytics.  
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       II. B. ii. d  Coronary Artery Bypass Graft (CABG) 
Coronary artery bypass grafting (CABG) was first used for acute MI in 1968 and 
quickly became the treatment of choice for patients with severe coronary disease. 
However, as advances in technology become available and experience with PCI 
increases, the additional benefits of CABG for patients with severe coronary disease 
have been reexamined.125 Data from a number of clinical trials comparing CABG to PCI 
with bare metal stents suggest similar survival in the two groups, with increased rates of 
revascularization at 5 years in PCI patients.126-128 Results from the SHOCK trial report 
that, in patients with cardiogenic shock, CABG may confer the same survival benefit as 
PCI. Among patients experiencing cardiogenic shock who underwent emergency 
revascularization, the 30 day-mortality rate was 45% for PCI patients and 42% for CABG 
patients.129 However, SHOCK investigators acknowledge that the survival benefit of 
surgery over PCI may not be fully evident before 1 to 5 years after hospitalization. More 
recent studies have documented a survival benefit for CABG over long-term follow-up, 
primarily because of the need for fewer repeat revascularizations in CABG 
patients.31,130,131 One recent trial did report better event-free survival in the short-term 
with CABG compared to PCI. The SYNTAX trial randomly assigned 1800 patients with 3 
vessel or left main CAD to CABG or PCI.125 Rates of major adverse cardiac or 
cerebrovascular events at 1 year were higher in the PCI group than in the CABG group 
(17.8% vs. 12.4%, respectively). Rates of death and MI were similar in both groups at 1 
year.  
The AHA has issued a recommendation that revascularization with CABG should be 
undertaken “if critical anatomy exists”, but that patients who have been stabilized and 
are not experiencing ongoing ischemic or hemodynamic compromise and who have 
experienced a significant decrease in LV function should delay surgery to allow for 
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Figure 2.5. Time-to-treatment and 1-
year mortality, 1994 - 2001
6
. 
maximum myocardial recovery.44 CABG is the preferred mode of revascularization in 
patients with cardiogenic shock who also have triple-vessel or left main disease to 
unload the heart and achieve complete revascularization.132 
  II. B. ii. e  Time to Revascularization 
The time elapsed from symptom onset to revascularization is a major predictor of 
outcomes after acute STEMI.133-135 Fibrinolytics confer a mortality benefit to STEMI 
patients by reducing infarct size, thereby salvaging healthy myocardium; favorably 
influencing infarct healing and myocardial remodeling, and reducing the potential for 
ventricular arrhythmia.96 However, these effects appear to be time-dependent, with most 
RCTs demonstrating benefits only when fibrinolytics are administered within 12 hours.  
The current “door-to-needle” recommendation for STEMI patients receiving 
thrombolytic therapy is 30 minutes, and the “door-to-balloon” recommendation for 
patients receiving angioplasty is 90 minutes.44 The time elapsed from symptom onset to 
initiation of fibrinolytic therapy is a direct predictor of infarct size and patient outcome, 
and the efficacy of fibrinolytic therapy 
diminishes with passing time.133,134 In 
animal studies, reperfusion at 90 minutes 
was found to salvage approximately half of 
the at-risk myocardium.135  
The beneficial effects of PCI appear to 
be less time dependent than those of fibrinolytics.136,137 For high-risk patients receiving 
PCI, time since symptom onset may be more predictive of outcomes than for low-risk 
patients.138 In an analysis of 27080 patients with STEMI or left-bundle branch block, 
Cannon, et al. documented increases in adjusted odds of mortality for door-to-balloon 
times of greater than two hours compared to door-to-balloon times of less than 2 hours. 
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Figure 2.6. Diagnostic Pathway for STEMI, 
NSTEMI and UA.  1 
In another observational study of 1791 patients treated by primary angioplasty, each 30-
minute delay was associated with an adjusted relative risk for 1 year mortality of 1.08 
(1.01 – 1.15).6 However, shorter balloon times may be a marker of a hospital’s general 
adherence to treatment guidelines or better quality of care, which are themselves 
associated with survival after hospital discharge.  
Shorter time-to-treatment may be differentially beneficial depending on the 
reperfusion strategy chosen and the time elapsed since symptom onset. Results from 
the PRAGUE-2 study suggest that for patients who present within 3 hours of symptom 
onset, mortality is similar between groups receiving PCI and those receiving 
fibrinolytics.139 In the CAPTIM trial, however, patients presenting within two hours of 
symptom onset had improved outcomes with thrombolytics compared with PCI.  This 
effect was reversed when the analysis was restricted to patients arriving beyond 2 hours, 
suggesting that patients with greater pre-hospital delays may benefit from PCI over 
fibrinolytics.140 
II. C      Acute MI Subclasses 
Beginning in 2000, recommendations for treatment of acute MI were made 
separately for two diagnostic subclasses: ST elevation myocardial infarction (STEMI) 
and non-ST elevation myocardial infarction 
(NSTEMI). While STEMI is 
characterized by an elevation of the ST 
segment as seen on an ECG, NSTEMI 
is characterized by ST-depression or T-
wave inversion and/or positive 
biomarkers of necrosis (e.g. troponin) in 
an “appropriate clinical setting” (eg., with other symptoms such as chest discomfort). As 
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shown in Figure 2.6, NSTEMI patients are typically differentiated from STEMI patients by 
electrocardiographic readings and from unstable angina patients by biomarker values. 
Clinical trials have historically focused on STEMI patients, which may translate to 
wider availability of STEMI-specific treatment information and more rapid implementation 
of evidence-based therapies for STEMI patients than for NSTEMI patients over time. 
However, NSTEMI patients compose the majority of acute MI patients seen in 
emergency departments,141 and the development of increasingly-sensitive biomarkers 
has led to reclassification of a large number of NSTEMI patients who would have 
previously been diagnosed as unstable angina. Additionally, a number of studies have 
reported lower rates of medication use and revascularization in NSTEMI patients despite 
data that supports the use of such therapies.142,143 As the proportion of MI patients 
diagnosed as NSTEMI rises, it is important to document patterns in this distinct 
population’s receipt of evidence-based medical treatment during an acute MI event.  
Few studies have examined differences in temporal trends in the treatment of 
patients presenting with STEMI compared to NSTEMI, and published reports have been 
limited to homogenous populations, short follow-up periods, or convenience samples 
that are not representative of the population at large. A 2010 analysis of trends in 
medical treatment for STEMI & NSTEMI patients documented initial disparities in the use 
of beta-blockers, lipid-lowering therapy, aspirin, and ACE Inhibitors in NSTEMI patients, 
with narrowing of these trends over time.142 However, this study was conducted in an all-
white population from a single geographic region, limiting generalizability of results to 
less homogenous populations. 
In a 2007 analysis of medical management of 2151 STEMI and NSTEMI patients, 
Montalescot and colleagues reported similar in-hospital and long-term prognosis among 
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STEMI and NSTEMI patients.144 However, NSTEMI patients underwent reperfusion less 
frequently and with greater time delays than STEMI patients. Data from the National 
Registry of Myocardial Infarction (1990-2006) reported similar improvements in quality of 
care over the study period for STEMI and NSTEMI patients.145  
Recommendations from the update to the AHA guidelines (2007) indicate that the 
average NSTEMI patient waits at least 2 hours after symptom onset to seek care, and 
that women affected by NSTEMI wait longer than men. This delay does not appear to 
have improved over the past decade.1 
Some evidence suggests a trend in practitioners taking an increasingly aggressive 
approach with the medical care of NSTEMI patients, such as performing evaluation of 
LV function, angiography and, if indicated, revascularization within 24 hours of hospital 
arrival.142,145 Recent interest has focused on the use of early, invasive strategies for 
NSTEMI, for example, diagnostic angiography with intent to revascularize without a prior 
non-invasive stress test or failure to respond to other medical treatment. A number of 
multicenter trials have shown similar outcomes with initial conservative and invasive 
strategies, and there may be risk associated with revascularization procedures. A meta-
analysis of conservative and invasive strategies for NSTEMI documented better patient 
outcomes associated with more invasive rather than more conservative strategies.146 
However, these results have not yet been confirmed in population-based settings.  
II. D Implementation of Medical Innovation 
Evidence provided by both clinical trials and observational studies has significantly 
contributed to the body of knowledge regarding medication use in MI patients. Clinical 
guidelines and recommendations for hospitalized MI treatment have been informed by 
both large observational studies such as ARIC, NRMI, Framingham, and MONICA, as 
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Figure 2.7. Conceptual Model of Diffusion, 
dissemination, and Implementation of 
Innovation
2
. 
well as large clinical trials such as COMMIT, ISIS, GISSI, and ASSENT However, the 
application of such knowledge in clinical practice is an integral step in positively 
impacting quality of care and improving outcomes in hospitalized MI. The theories of 
diffusion of innovation and system dynamics have helped to characterize the patterns by 
which new, evidence-based therapies are implemented in clinical practice.147-149 
Greenhalgh, et al (2004) expanded on these theories and, using results from a 
comprehensive review of the literature regarding diffusion of innovation in service 
organizations, developed a useful 
conceptual model describing the patterns 
by which change is adopted in service 
organizations such as medical facilities.2 
Greenhalgh identifies several integral 
factors in the implementation of such 
change, including relative advantage (in 
terms of either medical effectiveness or 
cost-effectiveness), compatibility with the 
adopters’ needs, the ability to experiment with the innovation on a limited basis, 
observability of intended benefits, and ability to reinvent or adapt the innovation to suit 
the adopters’ needs (Figure 2.7). Factors influencing implementation of change are said 
to lie on a continuum between passive diffusion (unplanned, informal, and largely 
mediated by peers) to active dissemination (centralized, formal, and likely to occur 
through vertical hierarchies). In the passive diffusion model, evidence from peer-
reviewed literature or medical conference presentations is thought to change clinical 
practice by trickling down along a “pressure gradient”, where magnitude of treatment 
effect and strength of the evidence are more likely to positively influence change in 
practice.150 However, several systematic reviews have suggested that typical 
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mechanisms of passive diffusion (attending conferences, browsing journals, listening to 
lectures) are unlikely to significantly impact clinical practice.151  Some evidence exists 
supporting the theory that training physicians to actively seek out and apply knowledge 
from clinical trials and observational studies can increase the rate of diffusion of 
innovation into practice.152 However, there are caveats to this approach, as the process 
of critically evaluating and applying evidence from the literature is time-consuming and 
can lead to information overload.153 Coupled with other barriers to implementation of 
change, including impaired knowledge or attitudes, group psychology, organizational 
characteristics, and economic factors, the burden of appropriately adopting medical 
innovation in a timely fashion often encumbers the translation of research into 
practice.149 
Empirical manifestations of these obstacles are well-illustrated in a number of reports 
on quality of care, guideline adherence, and trends in medication use. In a random 
telephone survey and medical record review conducted in 12 metropolitan areas in the 
United States, Mcglynn, et al (2003) reported that patients received only 54.9 percent of 
recommended care.154 One analysis of implementation of AHA guidelines for out-of-
hospital cardiac arrest found that agencies required an average of 416 days to 
implement new treatment guidelines.155 Gaps between evidence and implementation for 
treatment specific to MI have also been reported. The results of the beta-blocker Heart 
Attack Trial, published in 1981, reported a significant mortality benefit for MI patients.156 
However, 15 years later, only 62.5% of eligible patients were receiving the drug.157 A 
wealth of data from clinical trials supports the use of aspirin both in the acute phase of 
myocardial infarction and as a method of secondary prevention.158 However, analyses of 
two independent samples of office visits to US physicians revealed that even as late as 
2000, aspirin was prescribed for at most one third of non-contraindicated patients.159 
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More recent data indicates that this statistic has improved160 but gaps still exist between 
available evidence and real-world practice, especially for selected subgroups .161-166 
Obtaining a comprehensive picture of both the rate at which innovations diffuse into 
medical practice and the factors associated with their implementation or lack thereof is 
integral in the process of translating research into improvements in quality of care for 
diverse populations of MI patients.  
 
II. E Clinical trials versus community-based evidence 
While analyses of trends in treatment patterns of MI rely on observational data, 
studies of medication use and survival are often structured as randomized clinical trials.  
The RCT is generally considered the gold standard for causal inference in the study of 
treatment effects in cardiovascular disease epidemiology.167,168 However, results from 
RCTs are not always observed in the general population, and are seldom entirely 
consistent with results from other clinical trials. Clinical trials have stringent inclusion and 
exclusion criteria, and thus are not representative of the majority of patients who present 
to hospitals across the United States. Evidence from several studies indicates that 
clinical trial populations may not represent how MI patients are treated in actual clinical 
practice.169-171 In an analysis of 36 topics with conflicting results from over 200 trials in 
cardiology and gastroenterology, Horwitz, et al (1987) documented multiple contradictory 
results in RCTs of cardiovascular treatment and survival. Investigators concluded that 
inconsistency in RCT results stems from differences in the clinical setting and 
therapeutic evaluation, including study group selection, baseline variable differences, 
and management of intermediate outcomes.172 
Concern about bias introduced by unmeasured confounders has limited the use of 
data from observational studies in comparative analyses. A number of influential studies 
conducted in the 1970s and 1980s suggest that positive treatment effects are inflated in 
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Figure 2.8. Results of observational studies and 
randomized, controlled trials of cardiologic treatments
3
 
 
 
observational studies as compared with RCTs. One study of published results from 145 
papers on acute myocardial infarction found that 56% of nonrandomized trials reported 
positive treatment effects, compared with 30% of blinded RCTs.173 Another analysis 
compared results from RCTs and observational studies in 106 studies of 6 different 
therapies. Of 56 trials with historical controls, 44 (79%) reported a favorable treatment 
effect, compared with only 10 of 50 (20%) trials employing randomization.174 
Results from more recent analyses have challenged the belief that treatment effects 
are usually overestimated in studies using observational data. Benson, et al (2000) 
compared treatment effects observed in randomized clinical trials and observational 
studies published from 1985 to 
1998.3 In an analysis of results 
from 136 articles in 19 treatment 
areas, the authors reported little 
evidence of large differences in 
reported treatment effects between 
RCTS and observational studies for 
both cardiologic treatments (Figure 
2.8) and treatments in other disease 
areas.  
In another analysis of 99 studies 
in 5 clinical topic areas, Concato, et al (2000) documented “remarkably similar” results 
between observational studies and RCTs. The authors reported no systematic 
overestimation of the magnitude of treatment effects between observational studies and 
RCTs.175 In another analysis of 18 randomized trials and observational studies in health-
services research, McKee, et al (1999) reported that, while treatment effects vary 
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according to research design, neither the randomized nor the observational methods 
consistently produced greater magnitude of effects.176   
The Benson and Concato analyses had several advantages over similar 
comparisons conducted in the 1970s and 1980s. First, investigators were able to 
examine treatment effects in a variety of topic areas, including breast cancer, 
tuberculosis, trauma, and stroke. Second, because the studies used in the Benson and 
Concato analyses were more recent (1989 – 1998 and 1991-1995, respectively), they 
may have been able to account for bias using methodology not available in earlier 
studies. The non-randomized studies in the Chalmers and Sacks studies comprised 
trials using historical controls and unblinded trials instead of the cohort and case-control 
studies utilized in the Concato analyses, which may be less prone to the types of 
systematic bias introduced in the earlier non-randomized trials.  
Randomization in controlled trials reduces bias introduced by unmeasured 
confounders in observational studies.  However, contrary to conventional wisdom and as 
shown by comparisons of multiple results from both observational studies and RCTs, the 
absence of randomization in observational studies does not consistently result in the 
overestimation of treatment effects. Well-designed cohort and case-control studies with 
sophisticated modeling approaches that account for differential underlying mortality risk 
between treated and untreated patients provide valuable contributions to our knowledge 
of treatment effects in the general population. In the proposed study, careful inclusion of 
relevant covariates and the construction of propensity scores to account for likelihood of 
receiving treatment will minimize bias introduced by underlying differences in treatment 
groups.  
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 II. E. i      Underlying Treatment & Mortality Risk  
Patients who receive a particular medication may differ from those who are not on a 
number of covariates which may, in turn, affect survival probability. Bias may arise when 
treated subjects differ from untreated subjects on one or more covariates that affect both 
the likelihood that they will receive the treatment and their underlying survival probability, 
or baseline risk.177 In addition to conventional models that control for covariates affecting 
both probability of medication use and survival, it is possible to calculate scores 
representing a given patient’s exposure propensity and underlying risk of the outcome of 
interest to account for such differences.  
  II. E. i. a Disease Risk Scores 
In analyses of patient outcomes by medication, the use of efficient, risk-adjusted 
methods can substantially increase validity of study results. Disease risk scores (DRS) 
use clinical data to quantify underlying mortality or recurrent MI risk in a summary score, 
which is then treated as a confounder and controlled for in regression models. The 
Predicting Risk of Death in Cardiac Disease Tool (PREDICT) score was developed 
using 30-day, 2-year, and 6-year mortality data from the Minnesota Heart Survey.178 The 
score is a validated metric that predicts mortality in ACS patients from clinical 
presentation data, including cardiogenic shock, history of MI or cardiac procedures, age, 
severity of electrocardiographic changes, congestive heart failure, and Charlson 
Comorbidity Index. The PREDICT score has performed well in analyses of mortality in all 
three endpoints, with C-statistics in the range of 0.76 – 0.77.  In a comparison of 
Thrombolysis in Myocardial Infarction (TIMI) and PREDICT scores among MI patients in 
Olmstead County, the PREDICT score showed consistently better discriminant accuracy 
than did the TIMI score, regardless of time point or reperfusion strategy.179 
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      II. E. i. b Exposure Propensity Scores (PS) 
PS represent the probability that a given subject will receive a treatment of interest, 
based on that subject’s distribution of a selected set of covariates used to calculate the 
score. In randomized controlled trials, random assignment of subjects to treatment or 
control groups tends to balance the distribution of these covariates between the two 
groups. Because randomization is not possible in observational studies, a method called 
the propensity score may be utilized to construct matched sets or strata of subjects that 
tend to balance the distribution of covariates included in the score. This “virtual 
randomization” has been shown to result in equal distribution of included covariates in 
treated and untreated patients,180 with a number of simulation studies reporting 
comparable covariate distribution among groups after scores are calculated. 
      II. E. i. c      PS versus DRS 
Sturmer (2005) evaluated the behavior of DRS, PS, and conventional models in an 
analysis of NSAID use and all-cause mortality in Medicare beneficiaries.181 Investigators 
did not report major differences in the performance of PS, DRS, or conventional models 
in this population, even when using larger p-values for covariate inclusion for PS and 
DRS than for conventional models. However, there is some evidence that PS performs 
better (provides greater observed reduction of confounding) than conventional models 
when the outcome is rare (fewer than eight outcomes per included covariate)182 and 
better than DRS when the exposure is prevalent and the outcome is rare.183 In the 
proposed study population, we expect to have varying numbers of deaths depending on 
the cutpoint used (28-day or 1 year) and on the therapy used. Thus, we plan to evaluate 
both DRS and PS as potential effect-measure modifiers and confounders in trend and 
survival analyses.  
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III.     METHODS 
III.A     Study Population 
The design of the community surveillance component of the Atherosclerosis Risk in 
Communities (ARIC) study has been described. Briefly, it is a continuous retrospective 
surveillance study of hospitalized coronary heart disease (CHD) events with mortality 
follow-up designed to estimate trends in CHD incidence and mortality using standardized 
criteria and methods in four U.S communities: Forsyth County, North Carolina; Jackson, 
Mississippi; eight suburbs of Minneapolis, Minnesota; and Washington County, 
Maryland. Eligible events included inpatient and out-of-hospital deaths due to CHD and 
hospitalized nonfatal MI in 35-74 year old residents of these communities. Details of the 
sampling scheme for the community surveillance component in the ARIC study have 
been previously reported12. Trained abstractors investigate hospitalizations randomly 
sampled from annual discharge lists obtained from each hospital serving the four ARIC 
communities. Events were sampled on age, gender, community of residence and 
International Classification of Diseases (ICD-9) discharge codes, including 402, 410-414, 
427, 428, and 518.4.  Hospital records for sampled cases were reviewed, and relevant 
clinical information was abstracted onto standardized forms. Collected data items 
included presenting symptoms; timing of symptom onset; history of MI, angina, and other 
cardiovascular conditions; in-hospital medications, diagnostics, and medical procedures; 
laboratory values for a number of relevant cardiac biomarkers; and up to 3 sets of 
twelve-lead ECG readings. Regular and ongoing inter-abstractor agreement is assessed 
by evaluating concordance between data elements from a sample of cases abstracted 
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independently by two abstractors. Internal quality control procedures at the ECG reading 
Center were utilized to ensure reproducibility. 
 III. B MI diagnostics 
A computerized algorithm using electrocardiogram readings, history of chest pain, 
and cardiac biomarker levels (total creatinine phosphokinase(CK), creatinine 
phosophokinase-myocardial band (CK-MB), lactate dehydrogenase (LDH), troponin I, 
and troponin T) was used to assign an MI diagnosis to sampled hospitalized events. 
Using this algorithm, events were classified as one of the following: Definite MI, Probable 
MI, Suspected MI, no MI, or Unclassifiable. This analysis was restricted to events with a 
Definite or Probable MI diagnosis. Any event with abnormal or equivocal biomarker 
levels was further classified as ST- or non-ST elevation MI using pain presentation and 
Minnesota-coded electrocardiogram data from the first, third, or last ECG performed 
during hospitalization. Multiple hospitalizations occurring within 28 days were combined 
and treated as one event. Any event requiring review (for example, events where the 
computer-derived classification of definite MI disagreed with the ICD-9-CM codes for 
discharge diagnosis) was independently classified by two trained reviewers. Any 
disagreements in diagnoses were then adjudicated by a third reviewer.  
The ARIC study has classified myocardial infarction events into STEMI and NSTEMI 
using Minnesota coded electrocardiograms for all definite and probable MI events using 
variables in the SECA data file. Pain presentation and selected ECG variables are used 
to determine STEMI/NSTEMI status. For more information on STEMI/NSTEMI coding in 
ARIC, please see Appendix V. 
  
 
 
 
38 
  III.B.i   Quality Assurance for ascertainment 
Case ascertainment for hospitalized MI was assessed using a review of 
computerized criteria used to identify eligible cases. Two-day training sessions were 
held annually to standardize medical record abstracting, and abstractors were certified 
after successful completion of the certification exercises. Regular and ongoing inter-
abstractor agreement is assessed by evaluating concordance between data elements 
from a sample of cases abstracted independently by two abstractors. Internal quality 
control procedures at the ECG reading Center were utilized to ensure reproducibility. 
Blinded repeat codings of ECG readings from all cohort participants were compared by 
the Collaborative Studies Coordinating Center (CSCC).  
        III.B.ii   Quality assurance for Diagnostics 
Any event requiring review (for example, events where the computer-derived 
classification of definite MI disagreed with the ICD-9-CM codes for discharge diagnosis) 
were independently classified by two trained reviewers from the Mortality and Morbidity 
Classification Committee (MMCC). Any disagreements in diagnoses were then 
adjudicated by the MMCC chairman.  
    III.B.iii     Sampling 
The ARIC surveillance study uses various sampling procedures for identifying 
eligible deaths for investigation and eligible hospitalized cases for investigation. 
Sampling is a stratified random procedure based on underlying cause of death (UCOD) 
code or presence of certain ICD-9/10 discharge diagnosis codes. Because of this, all 
analyses were weighted by the inverse of sampling fractions.  
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III.C Medications 
Medications and procedures were obtained from hospital pharmacy records and 
medical record review during the abstraction process. Our analysis included data on 7 
medication classes: aspirin, beta blockers, calcium channel blockers, angiotensin-
converting enzyme (ACE) inhibitors, lipid-lowering medications, non-aspirin anti-platelet 
agents, and heparin; and 4 reperfusion/revascularization procedures: coronary artery 
bypass grafting (CABG), thrombolytic therapy (intracoronary or intravenous 
streptokinase, urokinase, anistreplase, anisoylated plasminogen streptokinase activator 
complex [APSAC], or tissue plasminogen activator [TPA] reperfusion), and coronary 
angioplasty (PCI) with or without the implantation of a stent. Each medication or 
procedure was classified as any receipt during hospitalization or at discharge (yes or 
no). Because abstraction of several therapies of interest began after 1987, risk estimates 
for the following therapies were estimated beginning with the first study year for which 
complete treatment information was available for all sampled events: heparin (beginning 
in 1992), ACE inhibitors (1992), non-aspirin anti-platelets (1997), lipid-lowering 
medications (1999) and stent implantation (1999).  
All-cause mortality was classified as a binary variable at 3 time points: 30 days, 90 
days, and 1 year after discharge. In the ARIC Surveillance study, deaths are ascertained 
in two ways. First, death certificates indicating cardiovascular disease as a possible 
UCOD are randomly sampled, reviewed and assigned a fatal diagnosis. Hospital records 
are abstracted for subjects with a fatal diagnosis of definite or probable MI. Second, 
hospital discharge records indicating potential MI admission are randomly sampled. 
Death at discharge is recorded for patients who die in-hospital. For patients who are 
discharged alive, National Death Index searches are performed to determine vital status 
one year after discharge.  
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 III.C.i  Time-to-treatment 
The ARIC HRA form classifies patients into 8 categories according to time from 
symptom onset of acute cardiac symptoms to arrival at this hospital: <1 hour, 1 – <2 
hours, 2 – <4 hours, 4 – <6 hours, 6 – <12 hours, 12 – <24 hours, 1 – <3 days, and >3 
days. Time from symptom onset to reperfusion is classified as <1 hour, 1 – <2 hours, 2 – 
<4 hours, 4 – <6 hours, 6 – <8 hours, and >8 hours. In analyses of trends in time-to-
treatment (Specific AIM 1.1), trends in the proportion of patients receiving treatment by a 
specific timepoint were evaluated (for example, proportion receiving treatment within 2 
hours of symptom onset).   
III. D Covariates 
 III. D.i Demographics 
Patient demographics in ARIC surveillance are obtained from medical record 
reviews. Gender (male or female), race (black or white/other), age, and health insurance 
(Medicare, Medicaid, prepaid health plan, HMO, other, or none) are available in the 
surveillance records and were be evaluated as potential effect measure modifiers or 
confounders as described in Section 3.5.2. 
 III. D. ii    Risk Scores 
The PREDICT score has been adapted for use with ARIC data.184 The score ranges 
from 0-24. One item used in the score, serum creatinine level, is not available in ARIC 
surveillance data, so renal failure was omitted from the PREDICT score calculation. The 
metric used for calculation of the PREDICT score is shown in Appendix I. We graphically 
confirmed the validity of the score in this cohort by examining the linear relationship 
between 30-day mortality rates and calculated PREDICT score. 
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Exposure propensity scores can be calculated for each patient using available 
covariate data. Given a treatment Z (Z=1 if treated, 0 if untreated) and observed 
covariates X, the PS is given as e(X) =prob(Z = 1|X), or the probability that a patient with 
given values for covariates X will be treated. One key feature of PS is that if it suffices to 
adjust for covariates X, it also suffices to adjusted for propensity score e(X), that is, 
ignorability given X implies ignorability given e(x).185 
In non-randomized studies, patients who receive a particular medication may differ 
from those who are not on a number of covariates which may, in turn, affect survival 
probability. Bias may arise when treated subjects differ from untreated subjects on one 
or more covariates that affect both the likelihood that they will receive the treatment and 
their underlying survival probability, or baseline risk.181 Analyzing patients with respect to 
propensity score (PS) is a method commonly used to address this problem.186 PS 
represents the probability that a given subject will receive a treatment of interest, based 
on that subject’s distribution of a selected set of covariates used to calculate the score. 
Given a treatment Z (Z=1 if treated, 0 if untreated) and observed covariates X, the PS is 
given as e(X) =prob(Z = 1|X), or the probability that a patient with given values for 
covariates X will be treated. The score is created by regressing receipt of each medical 
therapy in separate logistic regression models on a set of covariates. The probability of 
receipt of treatment for each subject, based on the covariates in the model, is retained 
and used as the propensity score for each.  After creation of the score, PS is entered as 
a continuous or categorical predictor in a regression model to estimate the association 
between the medical therapy of interest and mortality endpoints.  
Candidate variables for inclusion in the propensity score were selected based on 
literature reviews, clinical knowledge and directed acyclic graphs. Prior research has 
shown that including variables in the propensity score which related to the exposure but 
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not to the outcome reduces effect estimate precision without reducing bias, and may 
even increase bias.15,16  However, including covariates associated with the outcome but 
not the exposure increases the precision of the estimate without increasing bias.17 With 
these considerations in mind, we selected a standard set of clinical covariates that are 
known to be important risk factors for all-cause mortality: age (<45, 45-<55. 55-<65, 
65+), male gender, race-center cross classification (Jackson blacks, Jackson whites, 
Forsyth blacks, Forsyth whites, Minnesota whites and Washington whites), smoking 
status (ever vs. never), cardiogenic shock, congestive heart failure, cardiac arrest during 
hospitalization, history of diabetes,  STEMI diagnosis, study year (1987-1991, 1992-
1996, 1997-2001, 2002-2008), prior angioplasty, and prior CABG.  
 III. D. iii     Clinical and event Characteristics 
Event characteristics, including relevant clinical history, is abstracted from medical 
records and included in the hospital record abstraction form. Clinical variables of interest 
include past history of stroke, angina (any mention of prescribed nitroglycerin for chest 
pain or substernal symptoms precipitated by exercise and relieved by either nitroglycerin 
or rest), diabetes (diagnosed before or during hospitalization, or any type of oral 
hypoglycemic medication or insulin used prior to or during hospitalization), or previous 
CABG or PCI. The Charlson comorbidity was be calculated from ICD-9 discharge 
diagnosis codes for use in the PREDICT score calculation.  
Clinical comorbidities including prior MI, hypertension, diabetes mellitus, congestive 
heart failure, and stroke, and in-hospital complications, including cardiac arrest and 
cardiogenic shock, were documented. Event characteristics of interest included 
prehospital delay (<2 hours, >=2 hours; defined as the interval from onset of acute 
cardiac symptoms to hospital arrival), emergency medical services (EMS) transport, and 
length of hospital stay in days. 
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III. E     Statistical Analyses 
Several analyses in this work involve the evaluation of covariates as potential effect 
measure modifiers or confounders. The 
following Directed Acyclic Graphs (DAG) show 
the plausible causal relationships between 
each covariate of interest, based on biological 
plausibility and evidence from extant literature 
(Figure 3.1). In order to be considered a 
confounder, a covariate in a DAG must 1) 
have an arrow pointing to the exposure of 
interest (therapy use), 2) have an arrow 
pointing to the outcome of interest (mortality); 
and 3) not be on the causal pathway between 
the exposure of interest (therapy use) and the 
outcome of interest (mortality).187 Because of the potential bias introduced by controlling 
for covariates on the causal pathway,188 only those covariates that are not affected by 
therapy use should be controlled for. Thus, when we remove all arrows leading from 
therapy use to other covariates in the DAG (Figure 3.2), we see several unblocked 
backdoor paths involving demographics, risk scores, hospital characteristics, and clinical 
variables. Once these variables are evaluated as confounders and controlled for in the 
model(s), these backdoor pathways from therapy use to mortality are assumed to be 
blocked. 
 
 
 
Figure 3.1. Proposed DAG showing causal 
relationships between therapy use, 
covariates, and mortality 
Figure 3.2. DAG with arrows from 
therapy use removed  
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Equation 3.5.1. Simple linear model. 
 
ln(therapy) = 0 + 1(X1)   
where X1 = study year (0,1,2… n) 
 
Equation 3.5.2. Linear model with categorical 
indicators. 
 
ln(therapy) = 0 + 1(X1) + 2(X2) +3(X3)  
 
Exposure x (years) is divided into K categories 
indexed by k = 1,…K. For K=4, where X1,X2 and X3 
are (0, 1) disjoint indicator variables for 4 categories 
of study year. 
 
Equation 3.5.3. Components of the quadratic 
spline model to allow for departure from linearity in 
medication trends
5
. 
 
(a)  ln(P(therapy) = α + βx + γ1x
2
 + γ2s
2
2 + …+ γks
2
k 
where  
α= α*1, β=β*1, γ= γ*1  
sk = 0 if x <=ck, x -ck if x > ck. 
For all k>1, γk= γ*k- γ*k-1 represents the departure 
from linearity of the dose-response function for a 1-
unit increase in k. 
 
  III. E. i    Specific Aim I 
 Estimate the 21-year trends of in-hospital use of 5 pharmacological interventions for 
acute MI including aspirin, beta blockers, calcium channel blockers, IV heparin, ace 
inhibitors, statins, and 3 revascularization procedures, including thrombolytic therapy, 
percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). 
Each of the 11 medications and 
procedures were evaluated in 
separate regression models. Overall 
trends in medication and procedure 
use were first assessed using a 
simple linear model regressing 
medication use on treatment year 
and testing whether the slope of the 
regression line is statistically 
different from zero (Equation 3.5.1). 
However, because of the dynamic 
nature of medical advancements 
and their implementation in 
community practice, it was 
necessary to allow departure from linearity in the estimation of trends in medication use. 
To account for this, study year was divided into categories and build a logistic regression 
model with disjoint indicator variables for each study year category (Equation 3.5.2).   
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III. E. ii      Specific Aim II 
Evaluate how trends in medication and procedure use vary with important patient 
characteristics (age, demographics, multiple therapy, prior medical history, presenting 
severity) and hospital characteristics (bed size, teaching status, cardiac services 
capabilities). 
We examined changes in study population characteristics over the study period 
using chi-square tests for independence with Taylor Series variance estimation to 
account for the complex sampling scheme. The proportion of patients receiving each 
medication and procedure were calculated for all study years using weighted Poisson 
regression. Regression estimates obtained from these models were then age-
standardized to the 2000 US Census age distribution. We used multivariable loglinear 
regression to estimate average annual percent increases or decreases for each medical 
therapy overall and among STEMI and NSTEMI patients. In the figures, we present 
medication and procedure use for each study year; however, for ease of reporting and to 
promote stability in confidence interval estimates, events were grouped into intervals of 
5, 6, or 7 years for table presentation. Covariates in the regression model were selected 
based on prior knowledge and potential for confounding in this population. To examine 
use of reperfusion strategies in men and women over time, we calculated RRs and 95% 
CIs for all study years using multivariable Poisson regression with robust variance 
estimation.  
     III. E. iii      Specific Aim III 
Estimate the in-hospital, 28-day and one-year mortality associated with 8 
pharmacological interventions and revascularization procedures for acute MI. 
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Medications were first analyzed in a naïve model, where exposure will be classified 
as any exposure to the drug or procedure or no exposure to the drug or procedure. 
Logistic regression models controlling for exposure to all other medications were then 
used to estimate odds of 30-day and 1-year mortality for patients exposed to each drug 
or procedure.  
     III. E. IV     Specific Aim IV 
Evaluate how the association between survival and medical treatment varies with 
age, demographics, multiple therapy, prior medical history, presenting severity, clinical 
complications, PS/DRS and hospital characteristics 
We created medical therapy-specific propensity scores using multivariable logistic 
regression to model the association between the standard set of covariates and the 
receipt of each of 11 medical therapies. Because medications are rarely received in 
isolation, we created four sets propensity scores to account for the effect of other 
medications and procedures received during hospitalization. First, we created propensity 
scores using the standard set of clinical covariates that have been shown to be 
associated with survival after hospitalization, without consideration of receipt of other 
medications. Then, we created propensity scores with indicator variables representing all 
other medications and procedures in addition to this standard set of covariates. Third, 
we created propensity scores with the standard set of covariates and an indicator 
variable representing a dichotomized total number of other medical therapies received 
during hospitalization (<3 and >=3). Finally, we created a fourth set of propensity scores 
that included the standard covariate set and a variable representing the continuous total 
number of medications and procedures received during hospitalization. After creation of 
the scores, the model-specific distributions of covariates within PS quintiles were 
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compared, and model diagnostics were assessed.  C-statistic values for all models 
ranged from 0.63 to 0.85. Distributions of clinical covariates were comparable between 
treated and untreated patients within score quintiles, as were mean propensity scores. 
       III. E. v Power Analyses 
The null hypothesis in the proposed study is that there is no difference in odds of all-
cause mortality at discharge, 28 days, or one year between patients receiving a 
particular therapy and those who do not. For the following power analyses, we have 
chosen an a priori alpha value of 0.05 to minimize the probability of committing a Type 1 
error.  In the proposed study, we consider Type 1 errors to be more serious than Type 2 
errors. Of 61744 patients with complete HRA forms, 1619 (3%) died in hospital, 4958 
(8%) died at 28 days, and 6229 (10%) died within 365 days. Using these proportions, a 
total sample size of total definite/probable MI patients (n=17231) and a predefined alpha 
level, we calculated odds ratios and the corresponding power to detect those odds ratios 
for varied exposure and outcome proportions. 
I performed power calculations for the logistic regression components of the 
proposed analysis using StudySize 2.0 software (Frolunda, Sweden). One of our study 
aims is to characterize the proportion of definite and probable MI patients receiving 
particular therapies. Because the actual proportion of patients receiving each therapy is 
not yet known, we calculated power for 8 possible proportions of patients receiving 
individual MI treatment (X1=1), based on publicly available data. Power calculations for 
proportions of (X1=1) ranging from 0.05 to 0.4 in increments of 0.05 are shown for all-
cause mortality at hospital discharge, 28 days after discharge, and 365 days after 
discharge. For this analysis, the multiple correlation of X1 with X2 to Xp was set to 0.4. 
As shown in the tables below, our power for to detect differences in odds of mortality 
using the logistic regression model at treatment probability of 0.20 is excellent for ORs 
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above 1.4 for mortality at discharge and 1.2 for mortality at 28 days and 365 days after 
discharge. If the proportion of the sample receiving particular therapies is very small 
(0.05), our power to detect differences is inadequate for odds ratios under 2.0 for 
mortality at discharge and under 1.6 for mortality at 28 days and 365 days after 
discharge. However, we anticipate that most therapies will be used in at least 10% of 
definite and probable MI patients, a scenario in which we have approximately 72% 
power to detect ORs as small as 1.5 in the mortality at discharge group and 70-78% 
power to detect ORs as small as 1.3 in the 28-day and 265-day mortality groups (see 
tables below).  
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2. Power analysis for 365-day mortality endpoint  
Table 3.1. Power analysis for 28-day mortality endpoint  
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III. F Methodologic Strengths and Limitations  
 III.F.i       Study Population 
The ARIC surveillance study provides a geographically and racially diverse patient 
population in which to examine mortality and procedure use. The study includes 
validated data on hospitalized MI in four US communities spanning twenty years, during 
which a number of medical advancements were developed and first used in clinical 
practice. The hospital record abstraction form in ARIC surveillance provides a large 
number of important clinical variables, including laboratory values and 
electrocardiographic readings, which may be used to account for underlying mortality 
risk and probability of exposure to specific medical therapies.  
Follow-up for ARIC surveillance is currently limited to one year after hospital 
discharge, and available outcomes are limited to mortality as reported via death 
certificates. However, longer-term follow-up and other outcomes of interest (stroke, 
future revascularization, and recurrent MI) are possible with use of the ARIC cohort data. 
If associations of interest in short-term (1-year) mortality are documented, we may 
further explore these associations in using a subset of cohort members, for whom 20 
years of data on mortality, reinfarction, and adverse outcomes other than MI are 
available.  
 III.F.ii      Risk Prediction 
Complete data on patient-level contraindications to all medications of interest are not 
available in this study. However, I hope to account for variables that may influence both 
probability of receiving a specific therapy and risk of survival through the use of 
exposure propensity scores and/or disease risk scores. The PREDICT score is a 
validated metric that predicts mortality in ACS patients from clinical presentation data. 
The score has performed well in analyses of mortality in all three timepoints of interest in 
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this study, with C-statistics in the range of 0.76 – 0.77.  It has also showed comparatively 
better discriminatory accuracy than another risk score commonly used in analyses of MI 
patients.179 
 Exposure propensity scores represent another method for accounting for 
differential treatment probabilities in non-randomized patients. Probabilities of receiving 
a particular treatment are calculated based on a number of covariates in a regression 
model, and matched sets or strata of subjects are constructed using results from the 
model.  This “virtual randomization” has been shown to result in equal distribution of 
included covariates in treated and untreated patients.180 
 III.F.iii      CHD Mortality 
The outcome of interest in the present study is all-cause mortality as identified using 
publicly-available death records. One option when examining deaths related to 
hospitalization is to include only those deaths identified as CHD-related on the death 
certificate.  Cause of death on the death certificate is determined by health department 
trained nosologists according to the ICD-9, and underlying cause of death (UCOD) is 
then assigned using the Automated Classification of Medical Entities (ACME) system. 
However, the use of cause of death as listed on death certificates presents limitations. In 
one study of the validity of the death certificate in identifying CHD deaths in ARIC 
surveillance, Coady, et al (2001) found that the death certificate overestimated CHD 
mortality by nearly 20% in the four ARIC study communities.189 Furthermore, the false-
positive rate was found to vary significantly between study communities. Finally, in order 
to make valid comparisons to other community-based studies on case fatality, all-cause 
mortality is most appropriate. Because of the limitations inherent in using CHD-specific 
mortality and need for comparability to other studies, all-cause mortality will be examined 
as the outcome of interest in these analyses. 
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 III.F.iv     Specific Aims 1 & 2 
One strength of the analysis on trends in medical therapy is the use of quadratic 
splines to allow for departure from linearity in temporal trends. A common choice in the 
analysis of time trends is an arbitrary categorization of events (for example, dividing 
patients by study year 1987-1991, 1992-1995, etc). However, as shown by Greenland 
(1995), this method may present biased estimate when most subjects are exposed in a 
very narrow range within the categories or when exposure effects are more strongly 
seen at extreme ends of the exposure scale. This can lead to individuals at elevated risk 
being “submerged” by lower-risk members of their respective percentile categories. 
Quadratic splines minimize this problem by allowing for departure from linearity both 
within and between categories.  
 III.F.v     Specific Aims 3 & 4 
Of note is the decision to use logistic regression modeling instead of survival 
analysis or Cox proportional hazards models. For studies with short follow-up (up to 5 
years) and low incidence of event occurrence, the two models yield similar regression 
coefficients.190,191 192 Additionally, the asymptotic relative efficiency has been shown to 
be very close to 1 when there is a dichotomous covariate (in our study, therapy use) and 
identical censoring times for all subjects (in our study, 1 year after discharge). The 
proportional hazards assumption is an additional assumption required by the use of the 
Cox model, but not with the use of logistic regression. The short follow-up time, low 
incidence of event occurrence, and fewer model assumptions make the logistic 
regression modeling approach appropriate for this analysis. 
The analysis of survival and therapy use in MI is strengthened by the inclusion of a 
number of covariates that have been shown to affect both treatment and post-discharge 
mortality, specifically propensity scores. Additionally, because our observations are 
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naturally clustered within hospitals, there is potential for underestimation of error terms 
when using traditional survival or regression analysis, where all observations are treated 
as independent. To account for this, we plan to use multilevel (mixed) models in the 
model building process to obtain more accurate estimates of standard errors. Mixed 
models contain additional terms to allow for distributional effects (or “random effects”) in 
addition to the fixed effects observed in traditional regression. The random effects build 
a probability distribution into the model to account for the hierarchical structure of the 
data, and to allow for variation within data clusters (hospitals).  
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IV. RESULTS 
IV.A  Manuscript 1: Temporal trends in medical therapies for ST- and Non-ST 
Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities 
(ARIC) Surveillance Study  
 
IV.A.i    Introduction 
A wealth of data from clinical trials and observational studies has led to major 
advances in medical care for hospitalized MI over the past 3 decades.15,16,193 The 
availability of medical therapies for in-hospital management of MI is increasing 
annually,4,27 and the use of these therapies has substantially contributed to the 
decreasing MI death rates over the past three decades.12,16,23 However, the abundance 
of data on medical treatment for MI has done as much to set the standard of care as it 
has to diversify it. Evidence-based therapies and changes in guidelines typically take 
time to disseminate into clinical practice, and implementation of such therapies may vary 
by provider and geographic region.194 Monitoring both the patterns of use of evidence-
based therapies and the outcomes of treated patients is important in shaping future 
clinical decisions and further reducing mortality due to coronary heart disease (CHD). 
Reports from large observational studies have characterized recent temporal trends 
and treatment patterns for MI.8,22,25,29,195-197 Conclusions from existing reports have been 
limited, however, by selection, short follow-up periods, racially and/or geographically 
homogenous populations, and unvalidated clinical data. Furthermore, few studies have 
examined differences in temporal trends in the treatment of patients presenting with ST 
elevation myocardial infarction (STEMI) versus non-ST elevation myocardial infarction 
(NSTEMI), especially since this redefinition of acute MI resulted in a divergence in 
treatment recommendations by MI subclass beginning in 2000.198 Clinical trials have 
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historically focused on STEMI patients, which may translate to wider availability of 
STEMI-specific treatment information and more rapid implementation of evidence-based 
therapies for STEMI patients than for NSTEMI patients over time. Finally, a number of 
studies have documented disparities in the receipt of reperfusion by gender,199-201 but 
few have examined whether these disparities have improved over time.  
This report characterizes temporal trends in the in-hospital treatment of STEMI and 
NSTEMI patients over a 21-year period in the Atherosclerosis Risk in Communities 
(ARIC) Study surveillance communities, a large, population-based, racially and 
geographically diverse study population using validated clinical data and validated MI 
diagnostics.  
 IV.A.ii    Methods 
The design of the community surveillance component of the Atherosclerosis Risk in 
Communities (ARIC) study has been described.202 Briefly, it is a continuous retrospective 
surveillance study of hospitalized coronary heart disease (CHD) events with mortality 
follow-up designed to estimate trends in CHD incidence and mortality using standardized 
criteria and methods in four U.S communities: Forsyth County, North Carolina; Jackson, 
Mississippi; eight suburbs of Minneapolis, Minnesota; and Washington County, 
Maryland. Eligible events included inpatient and out-of-hospital deaths due to CHD and 
hospitalized nonfatal MI in 35-74 year old residents of these communities. Details of the 
sampling scheme for the community surveillance component in the ARIC study have 
been previously reported.203 Trained abstractors investigate hospitalizations randomly 
sampled from annual discharge lists obtained from each hospital serving the four ARIC 
communities. Events were sampled on age, gender, community of residence and 
International Classification of Diseases (ICD-9) discharge codes, including 402, 410-414, 
427, 428, and 518.4.  Hospital records for sampled cases were reviewed, and relevant 
 
 
55 
clinical information was abstracted onto standardized forms. Collected data items 
included presenting symptoms; timing of symptom onset; history of MI, angina, and other 
cardiovascular conditions; in-hospital medications, diagnostics, and medical procedures; 
laboratory values for a number of relevant cardiac biomarkers; and up to 3 sets of 
twelve-lead ECG readings. Regular and ongoing inter-abstractor agreement is assessed 
by evaluating concordance between data elements from a sample of cases abstracted 
independently by two abstractors. Internal quality control procedures at the ECG reading 
Center were utilized to ensure reproducibility.  
MI Diagnostics 
A computerized algorithm using electrocardiogram readings, history of chest pain, 
and cardiac biomarker levels (total creatinine phosphokinase(CK), creatinine 
phosophokinase-myocardial band (CK-MB), lactate dehydrogenase (LDH), troponin I, 
and troponin T) was used to assign an MI diagnosis to sampled hospitalized events. 
Using this algorithm, events were classified as one of the following: Definite MI, Probable 
MI, Suspected MI, no MI, or Unclassifiable. This analysis was restricted to events with a 
Definite or Probable MI diagnosis. Any event with abnormal or equivocal biomarker 
levels was further classified as ST- or non-ST elevation MI using pain presentation and 
Minnesota-coded electrocardiogram data from the first, third, or last ECG performed 
during hospitalization. Multiple hospitalizations occurring within 28 days were combined 
and treated as one event. Any event requiring review (for example, events where the 
computer-derived classification of definite MI disagreed with the ICD-9-CM codes for 
discharge diagnosis) was independently classified by two trained reviewers. Any 
disagreements in diagnoses were then adjudicated by a third reviewer.  
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Medical therapies 
Medications and procedures were obtained from hospital pharmacy records and 
medical record review during the abstraction process. Our analysis included data on 7 
medication classes: aspirin, beta blockers, calcium channel blockers, angiotensin-
converting enzyme (ACE) inhibitors, lipid-lowering medications, non-aspirin anti-platelet 
agents, and heparin; and 4 reperfusion/revascularization procedures: coronary artery 
bypass grafting (CABG), thrombolytic therapy (intracoronary or intravenous 
streptokinase, urokinase, anistreplase, anisoylated plasminogen streptokinase activator 
complex [APSAC], or tissue plasminogen activator [TPA] reperfusion), and coronary 
angioplasty (PCI) with or without the implantation of a stent. Each medication or 
procedure was classified as any receipt during hospitalization or at discharge (yes or 
no). Because abstraction of several therapies of interest began after 1987, trends for the 
following therapies were estimated beginning with the first study year for which complete 
treatment information was available for all sampled events: heparin (beginning in 1992), 
ACE inhibitors (1992), non-aspirin anti-platelets (1997), lipid-lowering medications 
(1999) and stent implantation (1999).  
Covariates 
Patient demographics were obtained from medical record reviews. Demographics of 
interest included gender (male or female), race (black or white/other) and age. Clinical 
comorbidities including prior MI, hypertension, diabetes mellitus, and stroke were 
collected. Event characteristics of interest included prehospital delay (<2 hours, 2-6 
hours, > 6 hours; defined as the interval from onset of acute cardiac symptoms to 
hospital arrival), emergency medical services (EMS) transport, and length of hospital 
stay in days.  
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In order to adjust for disease severity and clinical comorbidity, we utilized a modified 
Predicting Risk of Death in Cardiac Disease Tool (PREDICT) score.178 The score is a 
validated metric that predicts mortality in acute coronary syndrome patients from clinical 
presentation data, including cardiogenic shock, history of MI or cardiac procedures, age, 
severity of electrocardiographic changes, congestive heart failure, and Charlson 
Comorbidity Index. Data on renal function were not collected and therefore were omitted 
from our PREDICT score calculation.  
Exclusion criteria 
From 1987 – 2008, 32137 definite or probable MIs in subjects aged 35-74 years old 
were sampled in ARIC surveillance. We excluded patients whose race was not classified 
as black or white (n=658) and due to insufficient sample sizes, black patients who were 
sampled in Minnesota or Washington County, Maryland (n=493). After these exclusions, 
the final sample size for analysis was 30,986 definite or probable MI events.  
Statistical Analyses 
All estimates presented are weighted to account for the ARIC surveillance sampling 
scheme.204 We examined changes in study population characteristics over the study 
period using chi-square tests for independence with Taylor Series variance estimation to 
account for the complex sampling scheme. The proportion of patients receiving each 
medication and procedure were calculated for all study years using weighted Poisson 
regression. Regression estimates obtained from these models were then age-
standardized to the 2000 US Census age distribution. We used multivariable loglinear 
regression to estimate average annual percent increases or decreases for each medical 
therapy overall and among STEMI and NSTEMI patients. In the figures, we present 
medication and procedure use for each study year; however, for ease of reporting and to 
promote stability in confidence interval estimates, events were grouped into intervals of 
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5, 6, or 7 years for table presentation. Covariates in the regression model were selected 
based on prior knowledge and potential for confounding in this population. To examine 
use of reperfusion strategies in men and women over time, we calculated RRs and 95% 
CIs for all study years using multivariable Poisson regression with robust variance 
estimation. All models were run on the subset of definite and probable MI patients within 
the entire surveillance population to ensure correct calculation of standard errors.  To 
account for the complex sampling scheme, all analyses were conducted using SAS-
callable SUDAAN (release 9.2; Research Triangle Institute, Research Triangle Park, 
North Carolina). 
 IV.A.iii    Results 
Table 4.1.1 shows selected study population characteristics over time in 5-year 
intervals. From 1987 to 2008, 30,986 definite or probable MI events were sampled in the 
four study communities. Of these, 6106 (19.7%) were classified as STEMI, and 20302 
(65.5%) were classified as NSTEMI. The proportion of patients classified as neither 
STEMI nor NSTEMI (14.8%) remained stable over the study period.  Gender and age 
distribution remained relatively stable over the study period. Mean length of stay in days 
(95% CI) decreased substantially over the study period, from 10.1 (9.8, 10.5) days for 
patients in the first interval (1987-1991) to 6.4 (6.0, 6.8) days in the last interval. The 
prevalence of hypertension, diabetes, and stroke all increased throughout the study 
period, while the proportion of patients with a prior MI declined. The number of patients 
arriving by EMS transport increased during the study period, with 36.9% arriving by EMS 
in the first interval compared to 48.2% in the last interval. The proportion of patients 
classified as STEMI decreased from 19.6% in the first interval to 15.4% in the last 
interval, while the proportion of NSTEMI patients increased from 66.1% interval to 72.0% 
in the final interval.  
 
 
59 
Table 4.1.2 presents the proportion of patients receiving each medication and 
procedure of interest by year, age-standardized to the 2000 US Census population. We 
observed increases in the use of aspirin, beta blockers, ACE Inhibitors, lipid-lowering 
medications, non-aspirin anti-platelet agents, and heparin throughout the study period. 
Calcium channel blocker use decreased. The proportion of patients receiving 
thrombolytics decreased from 17% in 1987 to 0.8% in 2008. PCI use increased (15% in 
1987 to 37% in 2008) while the use of CABG decreased (17% in 1987 to 7% in 2008). 
Data on the use of stents was first collected in 1998.  Since then, the proportion of all MI 
patients receiving stents increased (9% in 1998 to 18% in 2008). Temporal trends for all 
patients and for STEMI/NSTEMI patients are illustrated for selected medications and 
procedures in Figure 4.1.1.  
Figure 4.1.2 presents the average annual percentage change in the use of 7 
medications and 4 procedures in ARIC surveillance from 1987-2008 by STEMI and 
NSTEMI classification, adjusted for sex, age, race*center classification, and PREDICT 
score. (Note: a reported percent change of 5% indicates an increase of 5% per year on 
average in the use of that particular medication or procedure during the study period). 
Similar trends were seen among STEMI and NSTEMI patients:  increases (%) were 
noted in the use of ACE inhibitors (STEMI:  6.4, 95% CI:  5.7 to 7.2; NSTEMI: 5.5, 95% 
CI: 5.0 to 6.1), non-aspirin anti-platelet agents (STEMI: 5.0, 95% CI: 4.0 to 6.0; NSTEMI: 
3.7, 95% CI: 2.7 to 4.7), lipid-lowering medications (STEMI: 4.5, 95% CI: 3.1 to 5.8; 
NSTEMI: 3.0, 95% CI:  1.9 to 4.1), beta blockers (STEMI: 2.7, 95% CI: 2.4 to 3.0; 
NSTEMI: 4.2, 95% CI:  3.9 to 4.4), aspirin (STEMI: 1.2, 95% CI: 1.0 to 1.3; NSTEMI: 1.9, 
95% CI:  1.6 to 2.1), and heparin (STEMI: 0.8, 95% CI:  0.4 to 1.3; NSTEMI: 1.7, 95% 
CI: 1.3 to 2.1). Calcium channel blocker use decreased for both STEMI (-8.8%, 95% CI: 
-9.6 to -8.0) and NSTEMI (-5.6, 95% CI:-6.1 to -5.1) patients over the study period.  
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Temporal trends in the receipt of reperfusion and revascularization procedures were 
also similar for STEMI and NSTEMI patients.  There were decreases in the use of 
thrombolytics (STEMI: -7.2%, 95% CI: -7.9 to -6.6; NSTEMI -9.8%, 95% CI: -10.7 to -
8.8) and CABG (STEMI: -2.4%, 95% CI: -3.6 to -1.2: NSTEMI: -2.5, 95% CI: -3.3 to -
1.6). PCI and stent use increased for both STEMI (PCI:  6.4; 95% CI:  5.8 to 7.0; stent: 
4.5; 95% CI:  2.7 to 6.2) and NSTEMI (PCI: 5.1; 95% CI:  4.5 to 5.7; stent: 1.3; 95% CI:  
-0.5 to 3.2) patients.  
We also examined trends in prehospital delay among STEMI and NSTEMI patients 
over time. The proportion of patients arriving in prespecified time intervals of <2 hours, 2-
6 hours, and >6 hours by STEMI/NSTEMI classification is shown in Figure 4.1.3. A 
higher proportion of STEMI patients arrived within 2 hours of symptom onset than 
NSTEMI patients during all study years. In models adjusting for age, sex, race, and 
center, the proportion of patients arriving within 2 hours decreased slightly over the study 
period (-0.46; -0.97, 0.05). Small annual percent changes were observed for both STEMI 
(0.14; -0.60, 0.90) and NSTEMI (-0.33; -1.0, 0.34) patients. The percent of patients 
arriving within 2 hours of symptom onset was relatively stable over the study period for 
both STEMI and NSTEMI patients.  
Finally, we examined reperfusion and revascularization rates in in male and female 
STEMI and NSTEMI patients. Risk ratios and 95% CIs comparing receipt of any 
reperfusion/revascularization strategy (PCI, PCI with stent, CABG, or thrombolytics) 
among men versus women for each study year are shown in Figure 4.1.4. Crude rates of 
reperfusion/revascularization were higher among men than among women for all study 
years. However, after adjustment for age, race*center, PREDICT score, and 
STEMI/NSTEMI classification, we did not observe significant differences in rates of 
reperfusion across gender strata. 
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 IV.A.iv    Discussion 
To our knowledge, this is the first study to present long-term trends in-hospital 
treatment for both STEMI and NSTEMI patients using validated clinical data.  The ARIC 
community surveillance study offers several advantages in the estimation of in-hospital 
MI treatment trends, including its large, geographically and racially diverse population, 
21-years of followup, population-based sampling scheme, and detailed clinical event 
data and validated MI diagnostics.   
We observed an increase in the use of 6 of the 7 medications of interest over the 
study period among STEMI and NSTEMI patients. The largest increases were in ACE 
inhibitors, non-aspirin anti-platelets, lipid-lowering medications, and beta-blockers. 
Smaller increases were noted for aspirin and heparin. These increases were significant 
after adjustment for age, gender, race and study center, and PREDICT score, did not 
differ by MI subclass, and are consistent with findings from other populations 
documenting increases in the use of aspirin,8,195,196,205,206 beta-blockers,8,68,195,196 and 
ACE inhibitors.8,195,196,207 Calcium channel blockers were the only class of medications 
for which we observed a decrease. The magnitude of decrease was similar to that 
reported in other populations.8,196  The overall results of increasing use of evidence-
based pharmacological interventions for hospitalized MI are consistent with those of 
other studies reporting trends in increasing quality of care and better guideline 
adherence for acute MI patients.145,208,209 The trends reported in this study are temporally 
consistent with the publication of the 1996 ACC/AHA Guidelines for the Management of 
Patients With Acute Myocardial Infarction, which recommended administration of aspirin 
immediately upon arrival, early administration of beta-blockers regardless of reperfusion 
strategy, and ACE Inhibitors for non-contraindicated patients. We also noted an increase 
in the use of non-aspirin anti-platelets following the 1999 update to the ACC/AHA 
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guidelines, which recommended Glycoprotein IIb/IIIa inhibitors for NSTEMI patients and 
clopidogrel as an acceptable substitute in patients contraindicated to aspirin.  
A number of studies of reperfusion in MI conducted in the early 1990’s reported 
persistent gender disparities in the receipt of PCI, CABG, and/or thrombolytics.199-201  We 
compared receipt of any reperfusion strategy among men and women over the study 
period. Crude estimates indicated that men were more likely than women to receive 
reperfusion at all time points. However, after adjustment for age, race*center, PREDICT 
score and STEMI classification, we no longer observed significant differences in the use 
of any reperfusion strategy in women compared to men. These findings are consistent 
with those of several studies that suggest gender differences in reperfusion rates may be 
accounted for by other clinical variables and event characteristics.210-212   
This study also presents trends in pharmaceutical treatments and reperfusion 
procedures by MI subclass. NSTEMI and STEMI were introduced as subclasses for 
acute MI in 2000.213 While both STEMI and NSTEMI release markers of necrosis that 
reflect acute MI, a classification of STEMI indicates acute myocardial ischemia or 
necrosis as evidenced by electrocardiographic data. Few studies have examined long-
term trends in management of NSTEMI and STEMI. Data from the National Registry of 
Myocardial Infarction (1990-2006) reported similar improvements in quality of care over 
the study period for STEMI and NSTEMI patients.145  
Increases in PCI with stent use were noted for both STEMI and NSTEMI. The rate of 
PCI use increased for both STEMI and NSTEMI throughout the study period. However, 
PCI use increased markedly among STEMI patients after 1999, contemporaneous to the 
publication of the AHA 1999 Update to Guidelines for the Management of Patients with 
Acute Myocardial Infarction, which recommended balloon inflation for PCI within 90 
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minutes of hospital arrival for eligible patients. Rates of CABG declined steadily 
throughout the study period for both STEMI and NSTEMI patients. The use of 
thrombolytics increased from 1987-1990 for both STEMI and NSTEMI patients, 
concurrent with the publication of results from two European trials, GISSI (1986) and 
ISIS-2 (1988), which reported mortality reductions with thrombolytics compared to 
placebo.214,215 However, the use of thrombolytics declined sharply after 1994, following 
the introduction of PCI and the publication of a number of trials reporting better clinical 
outcomes among patients treated with angioplasty compared to those treated with 
thrombolytics.216  
In a 2007 analysis of medical management of 2151 STEMI and NSTEMI patients, 
Montalescot, et al, reported similar in-hospital and long-term prognosis among STEMI 
and NSTEMI patients.144 However, NSTEMI patients underwent reperfusion less 
frequently and with greater time delays than STEMI patients. We noted similar 
disparities in reperfusion rates among NSTEMI and STEMI patients at all time points. 
However, significantly fewer NSTEMI patients presented within 2 hours of symptom 
onset, which may have affected eligibility for time-dependent reperfusion strategies such 
as thrombolytics. Additionally, clinical trial data suggests that early, invasive strategies 
for NSTEMI management may not confer any increased benefit in long-term survival 
compared to more selective or delayed invasive strategies.217-219 Further monitoring of 
long-term outcomes in NSTEMI patients treated with early invasive strategies compared 
to less-invasive strategies is needed. 
This study has a number of limitations. Several reports have underscored the 
importance of aggressive medical therapy early on in hospitalization for acute MI. One 
limitation of this analysis is the structure of the medication data element, which captures 
medications prescribed at any point during hospitalization or at discharge. We did not 
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have information on timing of administration, which limited our ability to make 
comparisons between early or delayed medication use. We were also unable to 
distinguish between medication use during hospitalization and at discharge.  
An additional limitation of this study is the possibility of confounding by indication. It 
is possible that the observed increases in medication use over time are due to 
increasing proportions of patients eligible for each therapy, especially medications which 
may also be used for other medical conditions besides acute MI (e.g., hypertension, 
heart failure).220 Because we do not have data on eligibility for each medication of 
interest, we were unable to examine the impact of patient-specific indications on 
temporal trends in MI therapy. However, we did utilize the PREDICT score to account for 
in-hospital complications and patient comorbidities, which are likely to influence 
treatment decisions.  To assess changes in the comorbidity burden in this population, we 
analyzed temporal trends in mean PREDICT score, a validated score that includes a 
comorbidity index and clinical event data. We did not observe significant changes in 
mean PREDICT score over time for among STEMI or NSTEMI patients.  
Finally, medication and procedure data were abstracted by chart review of sampled 
events from 4 US communities and may not be representative of practice patterns at all 
hospitals across the United States.  
We found trends of increasing use of evidence-based medicine for both STEMI and 
NSTEMI patients over the past 22 years. Future research should examine the effect of 
such trends on survival after hospital discharge and the broader public health impact of 
increasing dissemination of information and adherence to evolving guidelines. 
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Table 4.1.1. Characteristics of definite and probable MI patients overall and by event year groups in the ARIC Community Surveillance 
Study, 1987-2008.  
 Overall 1987-1991† 1992-1996 1997-2001 2002-2008 
Variable 
N=30986* 
(%) 
N=7524 
(%) 
N=7730 
(%) 
N=7380 
(%) 
N=8352  
(%) 
Age (mean, SD) 60.4 (12.0) 61.1 (10.9) 60.6 (11.7) 60.5 (11.9) 59.6 (13.7) 
Male gender 20360 (65.7) 4940 (65.7) 5207(67.4) 4813 (65.2) 5400 (64.7) 
Race-Center Classification      
Forsyth Black 3273 (10.6) 616 (8.2) 777 (10.0) 832 (11.3) 1047 (12.5) 
Forsyth White 8889 (28.7) 2103 (28.0) 2311 (29.9) 2130 (28.9) 2345 (28.1) 
Jackson Black 3805 (12.3) 621 (8.3) 752 (9.7) 1005 (13.6) 1427 (17.1) 
Jackson White 3276 (10.6) 1145 (15.2) 929 (12.0) 681 (9.2) 522 (6.3) 
Minnesota Whites 6320 (20.4) 1584 (21.1) 1566 (20.3) 1407 (19.1) 1762 (21.1) 
Washington Whites 5422 (17.5) 1454 (19.3) 1396 (18.1) 1324 (17.9) 1248 (15.0) 
Comorbidities      
Prior MI 10085 (32.7) 2784 (37.2) 2672 (34.7) 2417 (33.0) 2211 (26.5) 
Hypertension 19718 (63.9) 4285 (57.3) 4617 (59.9) 4855 (66.2) 5961 (71.6) 
Diabetes 7743 (34.4) --- 2034 (30.2) 2499 (34.1) 3188 (38.3) 
Stroke 2873 (9.3) 583 (7.8) 796 (10.3) 741 (10.1) 753 (9.0) 
PREDICT score
‡
 (mean) 9.5 (9.4, 9.5) 9.6 (9.5, 9.6) 9.5 (9.4, 9.5) 9.5 (9.4, 9.5) 9.3 (9.2, 9.4) 
Length of stay in days (mean) 7.9 (7.8, 8.1) 10.1 (9.8, 10.5) 8.4 (8.1, 8.6) 7.0 (6.7, 7.3) 6.4 (6.0, 6.8) 
Length of stay in days  (median) 6.0 8.0 7.0 5.0 4.0 
EMS transport 13048 (42.3) 2765 (36.9) 3171 (41.2) 3093 (42.1) 4019 (48.2) 
Prehospital delay
§
  <2 hours 8494 (27.4) 2102 (27.9) 2176 (28.2) 2085 (28.4) 2121 (25.4) 
Unknown 3632 (11.7) 912 (12.1) 857 (11.1) 821 (11.1) 1043 (12.5) 
Event Classification**      
STEMI 6106 (19.7) 1474 (19.6) 1926 (24.9) 1420 (19.3) 1284 (15.4) 
NSTEMI 20302 (65.5) 4970 (66.1) 4439 (57.4) 4869 (66.0) 6023 (72.1) 
*Weighted number of definite or probable MI events  
† Chi-square test  with Taylor Series variance estimation for independence of characteristics across study years (categorical variables) or one-way ANOVA 
(continuous variables) significant for all variables at p <0.001 
‡Modified PREDICT Score did not include data on kidney function 
§ Prehospital delay was defined as the interval from earliest symptom onset time to hospital arrival time 
** STEMI defined as ST-elevation at any site on either the first or last ECG 
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Table 4.1.2. Use of medical therapy and revascularization procedures overall and by event year groups in the ARIC Community 
Surveillance Study, 1987-2008*. 
 Overall 1987-1991‡ 1992-1996 1997-2001 2002-2008 
Therapy 
N=30986† 
% (SE) 
N=7524 
% (SE) 
N=7730 
% (SE) 
N=7380 
% (SE) 
N=8352  
% (SE) 
Medication      
Aspirin 82.4 (0.22) 65.7 (0.55) 85.0 (0.41) 89.0 (0.36) 89.3 (0.34) 
BB 68.0 (0.27) 45.3 (0.57) 61.3 (0.55) 75.5 (0.50) 87.9 (0.36) 
CCB 44.0 (0.28) 65.3 (0.55) 54.5 (0.57) 33.0 (0.55) 24.8 (0.47) 
ACEI 40.9 (0.28) --- 33.1 (0.54) 58.7 (0.57) 68.9 (0.51) 
Heparin 51.6 (0.28) --- 62.4 (0.55) 71.2 (0.53) 70.3 (0.50) 
Lipid-lowering medication 29.0 (0.26) --- --- 40.0 (0.57) 72.2 (0.49) 
Non-aspirin anti-platelets 27.9 (0.25) --- --- 45.5 (0.58) 62.5 (0.53) 
Procedures      
Thrombolytics 11.7 (0.18) 16.3 (0.43) 18.5 (0.44) 10.9 (0.36) 2.0 (0.15) 
PCI 28.0 (0.25) 15.6 (0.42) 25.0 (0.49) 30.4 (0.54) 39.7 (0.54) 
Stent 14.4 (0.20) --- --- 19.6 (0.46) 35.9 (0.53) 
CABG 14.3 (0.20) 15.6 (0.42) 18.1 (0.44) 14.5 (0.41) 9.5 (0.32) 
* Medication information for ACEI, Heparin, Lipid-lowering drugs, non-aspirin anti-platelets, and stents not collected during years  
    indicated by dashed lines (---) 
† Weighted number of definite or probable MI events 
‡ Chi-square test for independence with Taylor Series variance estimation significant for all variables at p <0.001 
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Figure 4.1.1. Medication and procedure use by year in STEMI & NSTEMI patients in 
ARIC Community Surveillance: 1987 - 2008. 
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Figure 4.1.2. Average annual % change in medical therapy and reperfusion procedure* use 
in STEMI and NSTEMI patients in ARIC Community Surveillance: 1987- 2008†. 
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Figure 4.1.3. Prehospital delay time* in STEMI and NSTEMI patients: The ARIC Community Surveillance 
Study: 1987- 2008. 
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Figure 4.1.4. Adjusted and unadjusted temporal trends in risk ratios comparing 
receipt of any reperfusion* strategy in men versus women: The ARIC Community 
Surveillance Study: 1987-2008.  
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IV.B Manuscript 2: Medication and reperfusion therapy and survival in a 
community-based setting of hospitalized myocardial infarction: The 
Atherosclerosis Risk in Communities Surveillance Study 
IV. B. i Introduction 
Acute myocardial infarction (MI) is the most common direct cause of mortality due to 
coronary heart disease (CHD) and approximately 16% of patients who experience an MI 
will die within one year of hospitalization.10 Death rates attributable to CHD have 
declined since the 1960s,13,14 with nearly half of the decrease in CHD mortality 
attributable to medical advancements.12 There is a rich literature of clinical trial data on 
medical therapies for MI and mortality. However, clinical trials are often conducted in 
highly-selected patient populations and may not represent what is observed in clinical 
practice.169-172 
Observational studies can provide a valuable perspective into the association 
between medical therapy and mortality after hospital discharge as observed in 
community-based, hospitalized settings. However, because treatment groups in 
observational studies are not randomly assigned, analyses of observational data have 
been limited by inability to account for bias introduced by differences in underlying 
mortality risk between treated and untreated patients.3 A number of methods have been 
proposed to address this limitation, including propensity scores (PS), which utilize a set 
of covariates to determine probability of treatment and result in a pseudo-randomization 
of subjects into exposure groups.221 However, few studies using PS to adjust for 
confounding have examined modeling strategies to account for the use of multiple 
therapies during a single hospitalized event. In this study, we examined the association 
between 30-day, 90-day, and 365-day mortality and receipt of 11 medical therapies 
commonly used for treatment of hospitalized MI in a population-based sample of the 
Atherosclerosis Risk in Communities (ARIC) Study surveillance communities. We used 
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five unique propensity score strategies to account for the non-randomized study design 
and the effect of multiple medical therapies on all-cause mortality after hospitalization in 
a large, community-based population of validated myocardial infarction events sampled 
over a period of 22 years.  
IV. B. ii Methods 
The design of the community surveillance component of the Atherosclerosis Risk in 
Communities (ARIC) study has been described.202 Briefly, it is a continuous retrospective 
surveillance study of hospitalized coronary heart disease (CHD) events with mortality 
follow-up designed to estimate trends in CHD incidence and mortality using standardized 
criteria and methods in four U.S communities: Forsyth County, North Carolina; Jackson, 
Mississippi; eight suburbs of Minneapolis, Minnesota; and Washington County, 
Maryland. Eligible events included inpatient and out-of-hospital deaths due to CHD and 
hospitalized nonfatal MI in 35-74 year old residents of these communities. Details of the 
sampling scheme for the community surveillance component in the ARIC study have 
been previously reported.203 Trained abstractors investigate hospitalizations randomly 
sampled from annual discharge lists obtained from each hospital serving the four ARIC 
communities. Events were sampled on age, gender, community of residence and 
International Classification of Diseases (ICD-9) discharge codes, including 402, 410-414, 
427, 428, and 518.4.  Hospital records for sampled cases were reviewed, and relevant 
clinical information was abstracted onto standardized forms. Collected data items 
included presenting symptoms; timing of symptom onset; history of MI, angina, and other 
cardiovascular conditions; in-hospital medications, diagnostics, and medical procedures; 
laboratory values for a number of relevant cardiac biomarkers; and up to 3 sets of 
twelve-lead ECG readings. Regular and ongoing inter-abstractor agreement is assessed 
by evaluating concordance between data elements from a sample of cases abstracted 
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independently by two abstractors. Internal quality control procedures at the ECG reading 
Center were utilized to ensure reproducibility.  
MI Diagnostics 
A computerized algorithm using evidence from electrocardiograms, history of chest 
pain, and cardiac biomarker levels (total creatinine phosphokinase(CK), creatinine 
phosophokinase-myocardial band (CK-MB), lactate dehydrogenase (LDH), troponin I, 
and troponin T) was used to assign an MI diagnosis to sampled hospitalized events. 
Using this algorithm, events were classified as one of the following: Definite MI, Probable 
MI, Suspected MI, no MI, or Unclassifiable. This analysis was restricted to events with a 
Definite or Probable MI diagnosis. Any event with abnormal or equivocal biomarker 
levels was further classified as ST- or non-ST elevation MI using pain presentation and 
Minnesota-coded electrocardiogram data from the first, third, or last ECG performed 
during hospitalization. Multiple hospitalizations occurring within 28 days were combined 
and treated as one event. Selected events requiring review (for example, events 
classified by computer as definite MI but without an ICD-10-CM 410 discharge diagnosis 
code) were independently classified by two trained reviewers. Any disagreements in 
diagnoses were then adjudicated by a third reviewer.  
Medical therapies 
Medications and procedures were obtained from hospital pharmacy records and 
medical record review during the abstraction process. Our analysis included data on 7 
medication classes: aspirin, beta blockers, calcium channel blockers, angiotensin-
converting enzyme (ACE) inhibitors, lipid-lowering medications, non-aspirin anti-platelet 
agents, and heparin; and 4 reperfusion/revascularization procedures: coronary artery 
bypass grafting (CABG), thrombolytic therapy (intracoronary or intravenous 
streptokinase, urokinase, anistreplase, anisoylated plasminogen streptokinase activator 
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complex [APSAC], or tissue plasminogen activator [TPA] reperfusion), and coronary 
angioplasty (PCI) with or without the implantation of a stent. Each medication or 
procedure was classified as any receipt during hospitalization or at discharge (yes or 
no). Because data on several therapies of interest were collected after 1987, risk 
estimates for the following therapies were estimated beginning with the first study year 
for which complete treatment information was available for all sampled events: heparin 
(beginning in 1992), ACE inhibitors (1992), non-aspirin anti-platelets (1997), lipid-
lowering medications (1999) and stent implantation (1999).  
All-cause mortality 
We analyzed three outcomes of interest: 30-day, 90-day, and 365-day all-cause 
mortality. Deaths were confirmed by medical record review, state death records, or 
linkage with the National Death Index. The 30, 60, and 90-day classifications represent 
the intervals from hospital admission date until date of death.  
Covariates 
Patient demographics were obtained from medical record reviews. Demographics of 
interest included gender (male or female), race (black or white/other), center (Minnesota, 
Washington County, Forsyth County, or Jackson) and age. Clinical comorbidities 
including prior MI, hypertension, diabetes mellitus, congestive heart failure, and stroke, 
and in-hospital complications, including cardiac arrest and cardiogenic shock, were 
documented. Event characteristics of interest included prehospital delay (<2 hours, >=2 
hours; defined as the interval from onset of acute cardiac symptoms to hospital arrival), 
emergency medical services (EMS) transport, and length of hospital stay in days.  
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Exclusion criteria 
From 1987 – 2008, 32137 definite or probable MIs in subjects aged 35-74 years old 
occurred in the ARIC surveillance communities. We excluded patients whose race was 
not classified as black or white (n=658) and due to insufficient sample sizes, black 
patients in Minnesota or Washington County, Maryland (n=493). After these exclusions, 
the final sample size for analysis was 30,985 definite or probable MI events.  
Propensity Scores  
In non-randomized studies, patients who receive a particular treatment may differ on 
a number of covariates from those who do not receive these treatments. These 
differences may, in turn, affect survival probability. Bias may arise when treated subjects 
differ from untreated subjects on one or more covariates that affect both the likelihood 
that they will receive the treatment and their underlying survival probability, or baseline 
risk.177 Analyzing patients with respect to propensity score (PS) is a method commonly 
used to address this problem.180 PS represents the probability that a given subject will 
receive a treatment of interest, based on that subject’s distribution of a selected set of 
covariates used to calculate the score. Given a treatment Z (Z=1 if treated, 0 if 
untreated) and observed covariates X, the PS is given as e(X) =prob(Z = 1|X), or the 
probability that a patient with given values for covariates X will be treated. The score is 
created by regressing receipt of each medical therapy in separate logistic regression 
models on a set of covariates. The probability of receipt of treatment for each subject, 
based on the covariates in the model, is retained and used as the propensity score for 
each.  After creation of the score, PS is entered as a continuous or categorical predictor 
in a regression model to estimate the association between the medical therapy of 
interest and mortality endpoints.  
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Variable selection 
Candidate variables for inclusion in the propensity score were selected based on 
literature reviews, clinical knowledge and directed acyclic graphs. Prior research has 
shown that including variables in the propensity score which related to the exposure but 
not to the outcome reduces effect estimate precision without reducing bias, and may 
even increase bias.222,223  However, including covariates associated with the outcome 
but not the exposure increases the precision of the estimate without increasing bias.224 
With these considerations in mind, we selected a standard set of clinical covariates that 
are known to be important risk factors for all-cause mortality: age (<45, 45-<55. 55-<65, 
65+), male gender, race-center cross classification (Jackson blacks, Jackson whites, 
Forsyth blacks, Forsyth whites, Minnesota whites and Washington whites), smoking 
status (ever vs. never), cardiogenic shock, congestive heart failure, cardiac arrest during 
hospitalization, history of diabetes,  STEMI diagnosis, study year (1987-1991, 1992-
1996, 1997-2001, 2002-2008), prior angioplasty, and prior CABG.  
We created medical therapy-specific propensity scores using multivariable logistic 
regression to model the association between the standard set of covariates and the 
receipt of each of 11 medical therapies. Because medications are rarely received in 
isolation, we created four sets propensity scores to account for the effect of other 
medications and procedures received during hospitalization. First, we created propensity 
scores using the standard set of clinical covariates that have been shown to be 
associated with survival after hospitalization, without consideration of receipt of other 
medications. Then, we created propensity scores with indicator variables representing all 
other medications and procedures in addition to this standard set of covariates. Third, 
we created propensity scores with the standard set of covariates and an indicator 
variable representing a dichotomized total number of other medical therapies received 
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during hospitalization (<3 and >=3). Finally, we created a fourth set of propensity scores 
that included the standard covariate set and a variable representing the continuous total 
number of medications and procedures received during hospitalization. After creation of 
the scores, the model-specific distributions of covariates within PS quintiles were 
compared, and model diagnostics were assessed.  C-statistic values for all models 
ranged from 0.63 to 0.85. Distributions of clinical covariates were comparable between 
treated and untreated patients within score quintiles, as were mean propensity scores 
(data not shown).  
Statistical Analyses 
All estimates presented are weighted to account for the ARIC surveillance sampling 
scheme.204  We used weighted multivariable loglinear regression to estimate risk ratios 
for the association between receipt of each medical therapy and 30-, 90-, and 365- day 
all-cause mortality. All models were run on the subset of definite and probable MI 
patients within the entire surveillance population to ensure correct calculation of 
standard errors.  To account for the complex sampling scheme, all analyses were 
conducted using SAS-callable SUDAAN (release 9.2; Research Triangle Institute, 
Research Triangle Park, North Carolina). 
We excluded all observations in the non-overlap regions of the propensity score 
distributions of the treated and untreated patients to ensure positivity.225  After this 
exclusion, we trimmed 5% of the observations at each tail of the propensity distribution 
to eliminate potential bias introduced by modeling the outcome of interest in subjects 
who were treated contrary to prediction.186 Finally, we examined ratio estimates for each 
medical therapy with propensity score modeled as either a continuous predictor or a 
categorical predictor, with PS included as 4 indicator variables representing quintiles of 
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the respective PS distributions for each medical therapy.226 Because estimates were 
similar, we present results obtained from models with quintiles of PS as predictors.  
IV. B. iii Results 
Table 4.2.1 shows selected characteristics for 30,986 subjects with MI and by strata 
of 3 outcomes of interest: all-cause mortality within 30 days, 90 days, and 365 days of 
discharge. The unadjusted risk of death within 30 days of hospitalization for definite or 
probable MI was 7.5%; within 90 days, 8.6%; and within 365 days, 10.0%. Compared to 
the entire population of hospitalized MI patients, those who died within 30 days of 
hospitalization were older, less likely to be male, black, have a history of stroke, have 
diabetes, arrive by EMS, and be classified as NSTEMI. Similar patterns were observed 
in patients who died within 90 days of hospitalization and those who died within 365 
days of hospitalization. Patients who died within 30, 90, or 365 days of hospitalization 
were less likely to have a prehospital delay time of less than 2 hours. Of all deaths that 
occurred within 30 days of hospitalization, a higher proportion were observed in earlier 
time periods (33.4% in 1987-1991) than in the later time periods (19.5% in 2002-2008). 
A similar pattern was observed for deaths within 90 days (34.3% in 1987-1991 vs. 32.5% 
in 2002-2008) and for deaths within 365 days (32.0% in 1987-1991 vs. 23.5% in 2002-
2008).  
Figure 4.2.1 shows the distribution of total medications per hospitalization by study 
year category. In this figure, events were grouped into intervals of 5, 6, or 7 years to 
promote stability in confidence interval estimates. The mean total number of medications 
per hospitalization increased from 1.77 (95% CI =1.73, 1.81) in the first study year 
interval to 4.76 (95% CI = 4.69, 4.83) in the fourth interval. Over time, the normalized 
distribution of total number of medications per hospitalization shifted to the right, 
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indicating a higher number of medications per hospitalization in recent years compared 
to earlier years. Additionally, the normalized distribution of number of medications per 
event appears to grow wider over time, indicating increasing variability in the number of 
medications per hospitalization within a given study year category.   
Table 4.2.2 presents the total percentage of patients receiving each medical therapy 
of interest over the study period (%; 95% CI) and the unadjusted risk of mortality at 30, 
90, and 365 days following hospitalization in patients who received each medical 
therapy. Aspirin was the most commonly used medication throughout the study period 
(82.4; 81.6, 83.2) followed by beta blockers (68.0; 67.1, 68.9), heparin (68.0; 66.9, 69.1), 
and lipid-lowering medications (67.3; 65.8, 68.8). Angioplasty was the most commonly 
used procedure (28.0; 27.3, 28.7), with over half of angioplasty patients receiving a stent 
(31.3; 30.1, 32.5). Crude mortality risks were lower for patients receiving all medications 
or procedure of interest than in the overall study population.  
Table 4.2.3 presents risk ratios estimating the association between receipt of each 
medical therapy and 30-day all-cause mortality by analytic strategy. The unadjusted 
estimates shown in the first column (Model A. Unadjusted) indicate positive survival 
benefits associated with each medication and procedure. The second column (Model B. 
PS Only) shows results from a model including quintile indicators for a propensity score 
derived from regression of medical therapy receipt on a set of standard clinical 
covariates. After inclusion of the PS, the crude survival effects were attenuated for all 
therapies except for IV-tPA and stent use. The third column (Model C. PS + all other 
medical therapies) shows effect estimates for each therapy in a model including a PS 
score derived from the same set of standard clinical covariates in Model B, with the 
addition of indicator variables for all other medical therapies of interest. After inclusion of 
other therapies, effect estimates (RR;[95% CI]) were substantially attenuated for aspirin 
80 
(0.66; [0.58, 0.76] to 0.91 [0.80 to 1.03) and moderately attenuated for non-aspirin anti-
platelets (0.74; [0.59, 0.92] to 0.92 [0.72 to 1.18]), IVTPA  (0.50; [0.41, 0.62] to 0.65 
[0.52 to 0.80]), stents (0.53 [0.40, 0.69] to 0.68 [0.49, 0.94]). Effect estimates remained 
stable for beta-blockers, calcium-channel blockers, lipid lowering medications, heparin, 
ACE Inhibitors, CABG and Angioplasty. The fourth column (Model D. PS + Number of 
other therapies [categorical]) shows results from a model including PS created from the 
standard set of covariates plus a variable representing dichotomized number of total 
medications per hospitalized event (<3, >3). Estimates from this model were similar to 
those from Model C, with the exception of stents (0.51 [0.42,0.63]) and IV-TPA (0.56 
[0.41, 0.75]), both of which showed increased mortality benefit in Model D compared to 
Model C. Finally, the fifth column shows risk ratios from a model controlling for a PS 
created from a model of the standard set of covariates plus the continuous number of 
total medical therapies per hospitalization. Effect estimates from this model were 
moderately attenuated for all medical therapies except for angioplasty and IVTPA, which 
were comparable to the estimates obtained from Model D.  
Tables 4 and 5 present the association between receipt of each medical therapy and 
90 and 365-day mortality (respectively), using the same strategies used to model 30-day 
mortality. Similar patterns in mortality by model strategy were observed for both 90- and 
365-day endpoints.  
IV. B. iv Discussion 
We observed negative associations between medication use and all-cause mortality 
at 30, 90 and 365 days after hospitalized myocardial infarction for beta-blockers, calcium 
channel blockers, aspirin, lipid-lowering medications, non-aspirin anti-platelets, ACE-
Inhibitors after adjustment for propensity scores created from a standard set of clinical 
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covariates. With the exception of non-aspirin anti-platelets, these associations were 
attenuated but remained significant after adding indicators for all other medical therapies 
to the PS regression model and after adding the continuous total number of medical 
therapies received to the model. With the exception of aspirin, none of the medications 
of interest showed a significant survival benefit when controlling for total number of 
medications. Similar patterns were observed when examining 90- and 365-day mortality 
endpoints. Our results are similar in magnitude and direction to those observed in a 
number of large-scale clinical trials for beta-blockers,53,54 aspirin,39,43 41 calcium channel 
blockers,64-67 ACEI Inhibitors,80,81 heparin,78,79 lipid-lowering medications.85-87 As has 
been observed in number of clinical trials, the mortality benefit of non-aspirin anti-
platelets was attenuated substantially after accounting for the use of other 
medications.46,48  
Negative associations between receipt of in-hospital procedures and 30-day mortality 
were observed with the inclusion of PS from a standard set of clinical covariates. These 
associations remained relatively stable for all four procedure groups after inclusion of 
variables representing number and type of other medical therapies, and similar patterns 
were observed for 90-day and 365-day mortality endpoints. These benefits are similar to 
those reported in clinical trials of PCI,110-112 PCI with stent,110,118 IVTPA,39,97-99 and 
CABG.126-128  
This study is unique in its analysis of survival and medication receipt in a community-
based, observational setting. Studies of causal inference of medication use and survival 
in cardiovascular disease are often structured as randomized clinical trials, widely 
considered the gold standard for causal inference in the study of treatment effects.167,168 
However, results from RCTs are not always generalizable to heterogenuous populations, 
and are seldom entirely consistent with results from other clinical trials. Clinical trials 
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have stringent inclusion and exclusion criteria, and evidence from several studies 
indicates that clinical trial populations may not represent how MI patients are treated in 
routine clinical practice.169-171 In an analysis of 36 topics with conflicting results from over 
200 trials in cardiology and gastroenterology, Horwitz, et al (1987) documented multiple 
contradictory results in RCTs of cardiovascular treatment and survival. Investigators 
concluded that inconsistency in RCT results stems from differences in the clinical setting 
and therapeutic evaluation, including study group selection, baseline variable 
differences, and management of intermediate outcomes.172 In the current study, we 
utilized rigorous methodology and careful covariate selection to minimize bias typically 
found in observational analyses.  
As the total number of medications administered or prescribed during each 
hospitalized event increases over time, so does the importance of accounting for the 
effects of other medications and procedures when analyzing the survival benefit of a 
particular therapy. There are few examples in the scientific literature of PS strategies to 
account for the use of multiple therapies during a single hospitalized event. To address 
this issue, we created four sets of propensity scores including the number and type of 
other medical therapies administered during hospitalization. Results from these models 
suggest mortality benefits at 30-, 60-, and 90-days for beta-blockers, aspirin, lipid-
lowering medications and ACE Inhibitors even after accounting for the presence of other 
medications during creation of PS.  Similar associations for all mortality endpoints were 
found when all variables used to create the propensity score were included in a standard 
loglinear regression model.  
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The ARIC community surveillance study offers a number of advantages in the study 
of medical therapy for acute MI and associated survival. The study population is a large, 
racially and geographically diverse community-based sample with validated myocardial 
infarction diagnostics. Because the ARIC study monitors hospitalized events over a 22 
year period, we were able to observe associations between medical therapy and 
mortality over a period of changing clinical practice landscape. Additionally, because of 
the large number of validated events in this population, we had adequate statistical 
power to detect medical therapy benefits for shorter-term timepoints.  Finally, because 
survival after myocardial infarction depends on a mix of factors, it is important to account 
for the key risk factors that determine survival after MI hospitalization. The ARIC 
surveillance study collects a large number of clinical covariates that have been shown to 
affect post-hospitalization mortality, including presence of comorbidities, procedure 
history, in-hospital complications, and STEMI/NSTEMI classification. This allowed us to 
account for the presence of potentially important confounders, an integral component to 
observational analyses of medication use and survival.  
Because mortality followup is limited to one year after hospital discharge, we were 
unable to examine the long-term benefits of medical therapies prescribed and 
administered during the course of hospitalization. It is possible that benefits conferred by 
the therapies in our analysis become more or less pronounced with time.  However, we 
did observe general stability in estimates between various timepoints within the one year 
mortality followup period of our study, so it is unlikely that there would be sudden 
divergence from the magnitude and/or direction of the observed benefits beginning at 
one year after hospitalization.  
Prior studies have shown less-than-optimal adherence in patients on CHD 
medication regimens.227-231 One study of statin therapy in an elderly population 
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documented a decline of nearly 50% in adherence after just 6 months of beginning the 
medication regimen.232 We were not able to determine patterns of medication use 
beyond discharge, and it is likely that each group of subjects identified as taking a 
particular medication includes a subset of individuals who did not fill prescriptions or 
were less than 100% adherent to prescribed medication regimens after discharge. 
However, as data from clinical trials and other observational studies have documented a 
survival benefit associated with the use of each medical therapy of interest in this 
analysis, including these patients would presumably reduce the observed effect of the 
medical therapy analyzed.  
Because the ARIC community surveillance study is observational in nature, 
assignment of patients to medical therapies of interest is not randomized. While we tried 
to account for major known confounders through the use of propensity scores, it is still 
possible that unmeasured confounders exist.  Additionally, the retrospective nature of 
the study limited our ability to account for the potential confounding effect of variables 
not collected as part of the current study protocol.  
As the proportion of MI patients receiving multiple medications during hospitalization 
continues to rise, so does the importance of accounting for the effect of all therapies 
when analyzing the survival benefit of a particular medication or revascularization 
procedure. Results from well-designed clinical trials and observational studies assessing 
the survival benefits associated with cardiovascular medications and procedures have 
contributed to substantial improvements in quality of care for hospitalized MI over the 
past decades. Future research should assess the benefit of emerging therapies from a 
comprehensive perspective of the course of in-hospital treatment for acute MI.  
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Table 4.2.1. Characteristics of definite and probable MI patients overall and by primary outcomes of 
interest in the ARIC Community Surveillance Study, 1987-2008. 
 
 All Patients 
N=30986* 
% (SE) 
 Death within  
30 Days† 
 Death within  
90 Days 
 Death within  
365 Days 
Covariate   N=2337 (7.5%)  N=2669 (8.6%)  N=3106 (10.0%) 
Age in years, mean (SD)  60.4 (0.09)  64.5 (0.28)  64.2 (0.29)   64.0 (0.28) 
Male gender  65.7 (0.42)  58.4 (1.53)  58.1 (1.51)  58.8 (1.4) 
Race-Center Classification         
Forsyth Black  12.3 (0.33)  13.0 (1.14)  13.6 (1.09)  16.9 (1.16) 
Forsyth White  10.6 (0.30)  11.6 (1.14)  12.0 (1.14)  11.1 (1.03) 
Jackson Black  10.6 (0.28)  15.1 (1.14)  15.6 (1.12)  16.7 (1.10) 
Jackson White  28.7 (0.42)   8.4 (1.45)  28.1 (1.43)  26.3 (1.30) 
Minnesota Whites  20.4 (0.36)   7.1 (1.19)  15.9 (1.12)  15.0 (1.03) 
Washington Whites  17.5 (0.30)   7.3 (0.93)  14.8 (0.87)  14.0 (0.81) 
Comorbidities         
Prior MI  32.6 (0.44)  34.8 (1.47)  35.2 (1.42)  36.6 (1.38) 
Hypertension  63.6 (0.44)  64.4 (1.53)  64.1 (1.52)  65.9 (1.42) 
Diabetes  25.0 (0.42)  26.8 (1.28)  26.2 (1.22)  28.0 (1.22) 
Stroke   9.3 (0.28)  17.2 (1.23)  17.7 (1.15)  17.4 (1.1) 
Length of stay in days, mean 
(SD) 
 
 7.9 (0.09) 
 
 7.9 (0.26) 
 
10.1 (0.37) 
 
10.3 (0.37) 
EMS transport  42.1 (0.47)  52.5 (1.59)  52.9 (1.55)  52.2 (1.47) 
Prehospital delay           
<2 hours  27.4 (0.40)  20.6 (1.26)  20.0 (1.18)  19.5 (1.08) 
Unknown  11.7 (0.39)  27.0 (0.60)  27.4 (1.75)  25.7 (1.61) 
Event Classification
§
         
STEMI  19.7 (0.32)  21.0 (1.13)  20.1 (1.05)  18.8 (0.96) 
NSTEMI  65.5 (0.44)  69.8 (1.42)  69.5 (1.40)  69.7 (1.34) 
Study Year         
1987-1991  24.3 (0.36)  33.4 (1.47)  34.2 (1.45)  32.0 (1.35) 
1992-1996  25.0 (0.38)  25.0 (1.37)  23.9 (1.30)  23.2 (1.24) 
1997-2001  23.8 (0.36)  22.2 (1.24)  21.4 (1.16)  21.3 (1.10) 
2002-2008  27.0 (0.42)  19.5 (1.26)  20.5 (1.29)  23.5 (1.29) 
Receipt of Reperfusion  46.2 (0.45)  20.7 (1.03)  20.3 (1.00)  20.0 (0.95) 
Number of Medications 
Received 
 
 
 
 
 
 
 
 
0  4.5 (0.25)  3.1 (0.23)  3.0 (0.23)  3.0 (0.23) 
1  9.8 (0.31)  8.9 (0.32)  8.7 (0.32)  8.5 (0.32) 
2  17.0 (0.36)  17.0 (0.37)  16.9 (0.38)  16.9 (0.38) 
3  21.2 (0.36)  21.6 (0.38)  21.7 (0.38)  21.8 (0.38) 
4+  47.5 (0.44)  49.5 (0.46)  49.7 (0.46)  49.8 (0.47) 
*Weighted number of definite or probable MI events  
† All-cause mortality from the first day of the hospitalized event 
‡ Prehospital delay was defined as the interval from earliest symptom onset time to hospital arrival time 
§ STEMI defined as ST-elevation at any site on either the first or last ECG 
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Table 4.2.2. Unadjusted risk of 30, 90, and 365-day mortality* and receipt of medications and procedures
†
: The ARIC Community 
Surveillance Study, 1987-2008. 
 % Receiving (95% CI) 30-Day (95% CI) 90-Day   (95% CI) 365-Day (95% CI) 
Medications            
Aspirin 82.4 81.6, 83.2  4.6 4.3, 4.9  5.4 5.0, 5.7  6.5 6.1, 6.9 
BB 68.0 67.1, 68.9  4.3 3.9, 4.7  5.1 4.7, 5.6  6.2 5.7, 6.7 
CCB 44.0 43.1, 44.9  6.3 5.8, 6.9  7.6 7.0, 8.3  8.8 8.1, 9.6 
ACEI 53.9 52.8, 55.0  4.7 4.2, 5.3  5.6 5.0, 6.3  7.3 6.6, 8.1 
Heparin 68.0 66.9, 69.1  5.4 5.0, 5.9  6.2 5.7, 6.8  7.5 7.0, 8.1 
Lipid-lowering medication 67.3 65.8, 68.8  2.7 2.3, 3.1  3.0 2.9, 4.0  4.9 4.3, 5.7 
Non-AAP 54.5 53.1, 55.9  3.2 2.8, 3.6  3.7 3.3, 4.2  4.9 4.4, 5.5 
Procedures            
CABG 14.3 13.7, 14.9  3.9 3.3, 4.5  4.7 4.0, 5.5  5.2 4.5, 6.1 
PCI 28.0 27.3, 28.7  2.6 2.2, 2.9  2.8 2.4, 3.2  3.3 2.9, 3.8 
IVT-PA 11.7 11.3, 12.1  4.6 3.9, 5.4  5.0 4.2, 5.8  5.5 4.7, 6.5 
Stent 31.3 30.1, 32.5  2.1 1.7, 2.7  2.4 1.9, 3.0  3.2 2.6, 3.8 
* All-cause mortality within 30, 90 OR 365 days of the hospital arrival date   
†
Medication or procedure use at any point during hospitalization or medication prescription at discharge 
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Table 4.2.3. Risk ratios for medical therapy use* and 30-day mortality
†
 among hospitalized MI patients by propensity score (PS) analytic strategy: 
The ARIC community surveillance study (1987 – 2008). 
  
Model A. 
Unadjusted 
 
Model B.  
PS: standard 
covariates only
‡
 
 
Model C.  
PS: standard 
covariates  + all 
other medical 
therapies§ 
 
Model D.  
PS: standard 
covariates + 
number of other 
therapies 
(categorical
**
) 
 
Model E.  
PS: standard 
covariates + number 
of other therapies 
(continuous) 
Therapy  RR 95%  CI  RR 95% CI  RR 95% CI  RR 95% CI  RR 95% CI 
Medication                
Beta blockers  0.30 0.26, 0.34  0.67 0.58, 0.76  0.71 0.62, 0.81  0.78 0.68, 0.89  0.89 0.75, 1.06 
Calcium channel 
blockers 
 0.74 0.66, 0.84 
 
0.80 0.70, 0.92  0.85 0.74, 0.98  0.77 0.66, 0.90  0.92 0.79, 1.08 
Aspirin  0.21 0.19, 0.24  0.66 0.58, 0.76  0.68 0.59, 0.78  0.65 0.57, 0.75  0.79 0.66, 0.95 
Lipid-lowering 
medications 
 0.22 0.17, 0.27 
 
0.51 0.40, 0.65  0.57 0.44, 0.73  0.71 0.53, 0.96  0.82 0.60, 1.13 
Non-aspirin anti-
platelets 
 0.32 0.27, 0.39 
 
0.74 0.59, 0.92  0.92 0.72, 1.18  0.91 0.70, 1.18  1.18 0.90, 1.54 
Heparin  0.59 0.51, 0.  0.86 0.73, 1.01  0.92 0.79, 1.07  0.96 0.81, 1.14  1.18 0.96, 1.44 
ACE Inhibitors  0.53 0.45, 0.61  0.66 0.56, 0.78  0.70 0.59, 0.82  0.71 0.60, 0.84  0.87 0.71, 1.06 
Procedure                
CABG  0.47 0.40, 0.56  0.60 0.50, 0.72  0.53 0.43, 0.66  0.64 0.53, 0.76  0.73 0.61, 0.88 
Angioplasty  0.27 0.23, 0.31  0.45 0.38, 0.54  0.48 0.39, 0.59  0.51 0.43, 0.61  0.61 0.51, 0.74 
IVTPA  0.58 0.48, 0.69  0.50 0.41, 0.62  0.65 0.52, 0.80  0.51 0.42, 0.63  0.57 0.46, 0.71 
Stent  0.88 0.69, 1.13  0.53 0.40, 0.69  0.68 0.49, 0.94  0.56 0.41, 0.75  0.67 0.49, 0.92 
* Medication or procedure use at any point during hospitalization or medication prescription at discharge 
†
 All-cause mortality within 90 days of the hospital arrival date   
‡
 5% of full propensity score range was trimmed from maximum values among untreated patients and minimum values among treated patients after 
elimination of non-overlapping scores 
§ Indicator variables representing 4 highest quintiles of propensity score values calculated separately for treated and untreated patients after 
eliminating non-overlapping scores and trimming 
**Categories of medication number were <3 and 3+ 
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Table 4.2.4. Risk ratios for medical therapy use* and 90-day mortality
†
 among hospitalized MI patients by propensity score (PS) analytic strategy: 
The ARIC community surveillance study (1987 – 2008). 
  
Model A. 
Unadjusted 
 
Model B.  
PS: standard 
covariates only
‡
 
 
Model C.  
PS: standard 
covariates  + all 
other medical 
therapies§ 
 
Model D.  
PS: standard 
covariates + 
number of other 
therapies 
(categorical
**
) 
 
Model E.  
PS: standard 
covariates + number 
of other therapies 
(continuous) 
Therapy  RR 95%  CI  RR 95% CI  RR 95% CI  RR 95% CI  RR 95% CI 
Medication                
Beta blockers  0.32 0.28, 0.36  0.70 0.62, 0.80  0.75 0.66, 0.85  0.80 0.71, 0.91  0.90 0.76, 1.05 
Calcium channel 
blockers 
 0.81 0.72, 0.91 
 
0.86 0.75, 0.99  0.92 0.80, 1.05  0.83 0.72, 0.97  0.98 0.85, 1.14 
Aspirin  0.23 0.20, 0.25  0.68 0.60, 0.77  0.71 0.63, 0.81  0.68 0.60 ,0.77  0.82 0.68, 0.98 
Lipid-lowering 
medications 
 0.25 0.20, 0.31 
 
0.57 0.44, 0.73  0.63 0.48, 0.82  0.73 0.55, 0.98  0.80 0.59, 1.08 
Non-aspirin anti-
platelets 
 0.34 0.28, 0.40 
 
0.74 0.60, 0.92  0.90 0.71, 1.14  0.87 0.67, 1.14  1.04 0.78, 1.38 
Heparin  0.61 0.53, 0.71  0.89 0.76, 1.03  0.94 0.81, 1.10  0.97 0.83, 1.14  1.15 0.95, 1.40 
ACE Inhibitors  0.58 0.50, 0.67  0.69 0.59, 0.81  0.73 0.63, 0.86  0.74 0.63, 0.87  0.88 0.73,1.06 
Procedure                
CABG  0.50 0.42, 0.60  0.64 0.54, 0.77  0.59 0.48, 0.74  0.67 0.56, 0.81  0.77 0.64, 0.93 
Angioplasty  0.26 0.22, 0.30 
 
0.44 0.37, 0.52  0.46 0.38, 0.56  0.49 0.41, 0.58  0.57 0.47, 0.68 
IVTPA  0.55 0.46, 0.65  0.50 0.41, 0.60  0.65 0.53, 0.79  0.52 0.42, 0.63  0.46 0.56 0.69 
Stent  0.26 0.21, 0.34  0.50 0.38, 0.65  0.60 0.44, 0.83  0.51 0.39, 0.68  0.59 0.44, 0.80 
* Medication or procedure use at any point during hospitalization or medication prescription at discharge 
†
 All-cause mortality within 90 days of the hospital arrival date   
‡
 5% of full propensity score range was trimmed from maximum values among untreated patients and minimum values among treated patients after 
elimination of non-overlapping scores 
§ Indicator variables representing 4 highest quintiles of propensity score values calculated separately for treated and untreated patients after 
eliminating non-overlapping scores and trimming 
**Categories of medication number were <3 and 3+ 
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Table 4.2.5. Risk ratios for medical therapy use* and 365-day mortality
†
 among hospitalized MI patients by propensity score (PS) analytic strategy: The 
ARIC community surveillance study (1987 – 2008). 
  
Model A. 
Unadjusted 
 
Model B.  
PS: standard 
covariates only
‡
 
 
Model C.  
PS: standard 
covariates  + all 
other medical 
therapies§ 
 
Model D.  
PS: standard 
covariates + 
number of other 
therapies 
(categorical
**
) 
 
Model E.  
PS: standard 
covariates + number 
of other therapies 
(continuous) 
Therapy  RR 95%  CI  RR 95% CI  RR 95% CI  RR 95% CI  RR 95% CI 
Medication                
Beta blockers  0.34 0.30, 0.38  0.69 0.61, 0.77  0.73 0.64, 0.82  0.79 0.69, 0.89  0.91 0.78, 1.07 
Calcium channel 
blockers 
 0.80 0.72, 0.90 
 
0.86 0.76, 0.98  0.91 0.80, 1.03  0.84 0.73, 0.96  0.98 0.85, 1.13 
Aspirin  0.24 0.22, 0.27  0.65 0.58, 0.74  0.70 0.62, 0.79  0.67 0.59, 0.76  0.82 0.69, 0.97 
Lipid-lowering 
medications 
 0.31 0.25, 0.37 
 
0.61 0.49, 0.76  0.69 0.54, 0.87  0.76 0.58, 1.00  0.83 0.63, 1.09 
Non-aspirin anti-
platelets 
 0.37 0.31, 0.43 
 
0.76 0.62, 0.93  0.94 0.76, 1.17  0.92 0.72, 1.17  1.08 0.83, 1.40 
Heparin  0.61 0.54, 0.70  0.89 0.77, 1.02  0.94 0.82, 1.09  0.99 0.85, 1.15  1.17 0.98, 1.39 
ACE Inhibitors  0.66 0.58, 0.76  0.73 0.62, 0.85  0.76 0.65, 0.88  0.77 0.66, 0.89  0.94 0.78, 1.12 
Procedure                
CABG  0.48 0.41, 0.57  0.62 0.52, 0.74  0.59 0.48, 0.72  0.65 0.55, 0.77  0.75 0.63, 0.90 
Angioplasty  0.26 0.23, 0.30  0.45 0.39, 0.53  0.49 0.41, 0.59  0.50 0.43, 0.59  0.59 0.50, 0.70 
IVTPA  0.52 0.44, 0.62  0.49 0.41, 0.60  0.63 0.52, 0.77  0.51 0.42, 0.62  0.56 0.46, 0.68 
Stent  0.28 0.23, 0.35  0.51 0.41, 0.65  0.63 0.48 0.83  0.56 0.44, 0.71  0.66 0.51, 0.86 
* Medication or procedure use at any point during hospitalization or medication prescription at discharge 
†
 All-cause mortality within 365 days of the hospital arrival date   
‡
 5% of full propensity score range was trimmed from maximum values among untreated patients and minimum values among treated patients after 
elimination of non-overlapping scores 
§ Indicator variables representing 4 highest quintiles of propensity score values calculated separately for treated and untreated patients after 
eliminating non-overlapping scores and trimming 
**Categories of medication number were <3 and 3+ 
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Figure 4.2.1. Normalized density plot of total medications per hospitalization for definite/probable MI by study 
year category: The Atherosclerosis Risk in Communities Surveillance Study (1987-2008).  
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V. CONCLUSIONS 
V. A. Overall study aims and findings 
A wealth of research over the past decades has contributed to better medical care 
and increased likelihood of survival for hospitalized MI patients. Numerous clinical trials 
and observational studies have expanded our knowledge of the most safe and 
efficacious treatments for MI; however, such data is useless if it is not implemented in 
the clinical care of MI patients.  Overall, the proposed aims of this study, to characterize 
changing practice patterns for STEMI and NSTEMI in a community-based setting over 
the past two decades and associated survival benefits, were met.  
This work documents the changing landscape of practice patterns for hospitalized MI 
in a representative, population-based sample over 22 years.  We observed an increase 
in the use of 6 of the 7 medications and 3 of the 4 procedures of interest over the study 
period among STEMI and NSTEMI patients. The overall study results of increasing use 
of evidence-based pharmacological interventions for hospitalized MI are consistent with 
those of other studies reporting trends in increasing quality of care and better guideline 
adherence for acute MI patients.145,208,209 We report trends that are temporally consistent 
with the publication of a number of major clinical trials and guideline updates, including 
the 1996 ACC/AHA Guidelines for the Management of Patients With Acute Myocardial 
Infarction, which recommended administration of aspirin immediately upon arrival, early 
administration of beta-blockers regardless of reperfusion strategy, and ACE Inhibitors for 
non-contraindicated patients. We also noted an increase in the use of non-aspirin anti-
platelets following the 1999 update to the ACC/AHA guidelines, which recommended 
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Glycoprotein IIb/IIIa inhibitors for NSTEMI patients and clopidogrel as an acceptable 
substitute in patients contraindicated to aspirin. However, PCI use increased markedly 
among STEMI patients after 1999, contemporaneous to the publication of the AHA 1999 
Update to Guidelines for the Management of Patients with Acute Myocardial Infarction, 
which recommended balloon inflation for PCI within 90 minutes of hospital arrival for 
eligible patients. These changes are evidentiary of information dissemination in the 
community of providers who treat MI, and rapid changes in clinical practice in response 
to new scientific discoveries are encouraging for policymakers, scientists, and providers 
with the goal of improving medical care for acute MI. 
The scientific literature contains numerous examples of randomized trial results that 
have not been replicated in clinical practice. We analyzed the association between 11 
medications and procedures that have shown to be beneficial in clinical trial populations 
and short-term mortality in a population-based sample of hospitalized MI. We 
documented substantial benefits associated with the use of beta-blockers, aspirin, lipid-
lowering medications, ACE Inhibitors, CABG, angioplasty, stents, and IV-TPA for 30-, 
90-, and 365-day all-cause mortality. These findings persisted when including indicators 
for number and type of other medications in the propensity score creation model. Few 
studies have examined such a large number of medical therapies for MI and associated 
survival.  A 2011 study  of 61 238 hospitalized STEMI patients in Sweden reported 
increases in the use of evidence based therapies over a 12-year study period and 
corresponding decreases in the rate of in-hospital complications and mortality.233 
However, as the authors note, this study was observational in nature, and investigators 
did not attempt to analyze the direct association between medical therapy use and 
mortality. A similar study assessed trends in long-term mortality and medication use in 
10352 patients in the UK. While the authors reported decreasing case-fatality and 
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increasing prescription of lipid-lowering drugs, beta-blockers, ACE-inhibitors and anti-
platelets, these trends were analyzed separately and no assessment of the potential 
effect of increasing medication use on case fatality was made.234  
V.B. Strengths 
To our knowledge, this is the first study to present long-term trends in-hospital 
treatment for both STEMI and NSTEMI patients using validated clinical data.  The ARIC 
community surveillance study offers several advantages in the estimation of in-hospital 
MI treatment trends, including its large, geographically and racially diverse population, 
22-years of followup, population-based sampling scheme, and detailed clinical event 
data and validated MI diagnostics. Because the ARIC study was conducted over a 
period of 22 years, we were able to observe associations between medical therapy and 
mortality over a period of changing clinical practice landscape. Additionally, because of 
the large number of validated events in this population, we had adequate statistical 
power to detect medical therapy benefits for shorter-term timepoints.  Finally, because 
fatal events after myocardial infarction have a complex etiology, it is important to account 
for the key risk factors that determine survival after MI hospitalization. The ARIC 
surveillance study collects a large number of clinical covariates that have been shown to 
affect post-hospitalization mortality, including presence of comorbidities, procedure 
history, in-hospital complications, and STEMI/NSTEMI classification. This allowed us to 
account for the presence of potentially important confounders, an integral component to 
observational analyses of medication use and survival.  
Additionally, few studies have compared the performance of propensity scores in 
analyses of mortality after hospitalization for MI. Even few have examined the behavior 
of such scores after accounting for use of other medications and procedures. As the use 
of propensity scores becomes more common in epidemiologic research, we hope that 
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this study will inform future research concerned with the appropriate use of risk scores in 
observational cohorts. 
V.C. Limitations 
This study has a number of limitations. Several reports have underscored the 
importance of aggressive medical therapy early on in hospitalization for acute MI. One 
limitation of this analysis is the structure of the medication data element, which captures 
medications prescribed at any point during hospitalization or at discharge. We did not 
have information on timing of administration, which limited our ability to make 
comparisons between early or delayed medication use. We were also unable to 
distinguish between medication use during hospitalization and at discharge.  
An additional limitation of this study is the possibility of confounding by indication. It 
is possible that the observed increases in medication use over time are due to 
increasing proportions of patients eligible for each therapy, especially medications which 
may also be used for other medical conditions besides acute MI (e.g., hypertension, 
heart failure).220 Because we do not have data on eligibility for each medication of 
interest, we were unable to examine the impact of patient-specific indications on 
temporal trends in MI therapy. However, we did utilize the PREDICT score to account for 
in-hospital complications and patient comorbidities, which are likely to influence 
treatment decisions.  To assess changes in the comorbidity burden in this population, we 
analyzed temporal trends in mean PREDICT score, a validated score that includes a 
comorbidity index and clinical event data. We did not observe significant changes in 
mean PREDICT score over time for among STEMI or NSTEMI patients.  
Because mortality followup in ARIC surveillance is limited to one year after hospital 
discharge, we were unable to examine the long-term benefits of medical therapies 
prescribed and administered during the course of hospitalization. It is possible that 
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benefits conferred by the therapies in our analysis become more or less pronounced 
with time.  However, we did observe general stability in estimates between various 
timepoints within the one year mortality followup period of our study, so it is unlikely that 
there would be sudden divergence from the magnitude and/or direction of the observed 
benefits beginning at one year after hospitalization.  
Prior studies have shown less-than-optimal adherence in patients on CHD 
medication regimens.227-231 One study of statin therapy in an elderly population 
documented a decline of nearly 50% in adherence after just 6 months of beginning the 
medication regimen.232 We were not able to determine patterns of medication use 
beyond discharge, and it is likely that each group of subjects identified as taking a 
particular medication includes a subset of individuals who did not fill prescriptions or 
were less than 100% adherent to prescribed medication regimens after discharge. 
However, as data from clinical trials and other observational studies have documented a 
survival benefit associated with the use of each medical therapy of interest in this 
analysis, including these patients would presumably reduce the observed effect of the 
medical therapy analyzed.  
Because the ARIC community surveillance study is observational in nature, 
assignment of patients to medical therapies of interest is not randomized. While we tried 
to account for major known confounders through the use of propensity scores, it is still 
possible that unmeasured confounders exist.  Additionally, the retrospective nature of 
the study limited our ability to account for the potential confounding effect of variables 
not collected as part of the current study protocol.  
Finally, medication and procedure data were abstracted by chart review of sampled 
events from 4 US communities and may not be representative of practice patterns at all 
hospitals across the United States.  
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V.D. Public Health Implications 
 Results from well-designed clinical trials and observational studies assessing the 
survival benefits associated with both conventional and innovative cardiovascular 
medications and procedures have contributed to large improvements in quality of care 
for hospitalized MI over the past decades. National guidelines put forth by expert panels 
and organizations are frequently updated to reflect breakthroughs in the study of MI 
therapies. However, recent studies suggest that there are persistent gaps between 
available evidence in support of specific therapies and their use in clinical practice at the 
community level.  
The rate at which innovations are implemented in community-based settings varies 
based on geography, hospital characteristics and provider preferences. Identifying the 
factors associated with medical therapy use (or lack thereof) is integral to informing 
interventions aimed at increasing the rate of diffusion and implementation of innovative 
therapies for MI. As such gaps and their associated factors are identified, policy-makers 
and hospital administrators will be better equipped to implement changes that are likely 
to improve the standard of care for hospitalized MI patients. 
This project is a cross-sectional community surveillance study of therapy use and 
mortality in hospitalized MI patients identified over 22 years in 4 U.S. communities. While 
clinical trial data is often considered the gold standard in the study of medical therapies 
and survival, such data often represent highly-selected patient groups, and thus may not 
be generalizable to the population of hospitalized MI in the community. The present 
study included a geographically and racially diverse population of patients followed over 
a long period of time, and the results will have implications for a broader patient 
population than is often possible with highly-selected clinical trial groups. 
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All observational studies have a significant caveat: differences in underlying mortality 
risk between treated and untreated patients and confounding by indication are more 
likely to be present when patients are not randomized to a particular treatment. 
However, the use of propensity scores helps to minimize the potential bias introduced by 
these differences. Additionally, we used a number of different PS strategies in a 
community-based population may help to inform future research efforts analyzing 
outcomes in non-randomized patient populations.  
Better medical care in the US is leading to lower case fatality rates for a number of 
acute events and longer life expectancy for those living with chronic conditions. Thus, 
the proportion of MI patients with a history of cardiovascular disease or who are living 
with other comorbidities is rising. Clinical management of MI becomes particularly 
complex when treating patients with a number of other medical problems or patients of 
advanced age. We documented a rising number of medications prescribe during 
hospitalization from 1987-2008. As the proportion of MI patients receiving multiple 
medications during hospitalization continues to rise, it become increasingly important to 
account for the effect of all therapies when analyzing the survival benefit of a particular 
medication or revascularization procedure. In this study, we analyzed the effect of other 
medications and revascularization procedures by creating a number of different 
propensity scores reflecting the number and type of other medical therapies  
V.E. Future directions 
The rate of implementation of medical innovation is not consistent across all 
hospitals treating acute MI. Certain providers may apply scientific advances to the 
clinical care of MI more rapidly than others, which may result in disparities in care for MI 
patients.  Additionally, there is an increasing variety of medical therapy options for acute 
MI, and the decision to use one over another may depend on a number of factors, 
98 
 
including provider preferences, patient frailty and life expectancy, comorbidities, 
insurance coverage, and hospital resources. Future studies should examine barriers to 
providing state-of-the-art care for MI and evaluate strategies to improve compliance with 
changing national guidelines. 
A number of reports have documented less-than-perfect adherence to medication 
regimens following MI hospitalization. Future studies should evaluate factors associated 
with adherence to both pharmaceutical regimens and lifestyle recommendations in 
patients following acute MI. Education efforts targeting risk factors for recurrent MI and 
other cardiovascular diseases should be rigorously evaluated to determine the most 
cost-effective and efficacious strategies for reducing the risk of a future MI event. 
Finally, new methods in comparative effectiveness analysis, the field of study in 
which one treatment is evaluated in comparison to at least one other established 
treatment in an attempt to assess their effectiveness relative to one another, hold 
promise for informing providers faced with a variety of treatment options. Results from 
these studies, along with those from cost-benefit analyses, will continue to inform 
patients and providers of the most safe, effective, and economic medical therapies 
available for the treatment of acute MI.  
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Table S.1.2. STEMI: Use of medical therapy and revascularization procedures overall and by event year groups in the ARIC Community 
Surveillance Study, 1987-2008*. 
 Overall 1987-1991‡ 1992-1996 1997-2001 2002-2008 
Therapy 
N=6106† 
(%)§ 
N=1475 
(%) 
N=1926 
(%) 
N=1420 
(%) 
N=1284 
(%) 
Medication      
Aspirin 89.6 (0.39) 77.9 (1.08) 91.1 (0.65) 93.5 (0.66) 96.2 (0.53) 
BB 75.6 (0.55) 57.0 (1.29) 73.4 (1.01) 82.9 (1.00) 92.2 (0.75) 
CCB 37.4 (0.62) 60.6 (1.27) 44.6 (1.13) 26.5 (1.17) 12.2 (0.91) 
ACEI 42.6 (0.63) --- 35.7 (1.09) 63.7 (1.28) 78.3 (1.15) 
Heparin 60.3 (0.63) --- 74.9 (0.99) 86.0 (0.92) 78.1 (1.15) 
Lipid-lowering medication 26.3 (0.56) --- --- 37.1 (1.28) 84.0 (1.02) 
Non-aspirin anti-platelets 31.9 (0.60) --- --- 59.0 (1.31) 84.3 (1.02) 
Procedures      
Thrombolytics 33.9 (0.61) 44.1 (1.29) 45.6 (1.13) 33.1 (1.25) 5.4 (0.63) 
PCI 42.6 (0.63) 24.2 (0.01) 34.4 (1.08) 47.0 (1.32) 71.1 (1.27) 
CABG 14.9 (0.46) 15.3 (0.94) 18.5 (0.89) 15.7 (0.96) 8.0 (0.76) 
Stent 20.5 (0.52) --- --- 29.1 (1.21) 65.1 (1.33) 
* Medication information for ACEI, Heparin, Lipid-lowering drugs, non-aspirin anti-platelets, and stents not collected during years  
    indicated by dashed lines (---) 
† Weighted number of definite or probable MI events 
‡ Chi-square test for independence with Taylor Series variance estimation significant for all variables at p <0.001 
§
 Percentages calculated using years in which data was collected for each therapy 
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Table S.1.3. NONSTEMI: Use of medical therapy and revascularization procedures overall and by event year groups in the ARIC 
Community Surveillance Study, 1987-2008*. 
 Overall 1987-1991‡ 1992-1996 1997-2001 2002-2008 
Therapy 
N=20302† 
(%)§ 
N=4970 
(%) 
N=4439 
(%) 
N=4869 
(%) 
N=6023  
(%) 
Medication      
Aspirin 81.8 (0.27) 63.5 (0.68) 84.7 (0.54) 88.3 (0.46) 89.4 (0.40) 
BB 67.1 (0.33) 43.0 (0.70) 57.9 (0.74) 74.9 (0.62) 87.5 (0.43) 
CCB 45.9 (0.35) 67.9 (0.66) 59.2 (0.74) 34.5 (0.68) 27.1 (0.57) 
ACEI 40.6 (0.34) --- 31.0 (0.69) 57.9 (0.71) 66.6 (0.61) 
Heparin 50.9 (0.35) --- 60.8 (0.73) 69.5 (0.66) 70.3 (0.59) 
Lipid-lowering medication 30.8 (0.32) --- --- 41.3 (0.71) 70.4 (0.59) 
Non-aspirin anti-platelets 28.4 (0.32) --- --- 44.1 (0.71) 59.5 (0.63) 
Procedures      
Thrombolytics 5.7 (0.16) 9.5 (0.42) 8.7 (0.42) 4.8 (0.31) 1.0 (0.13) 
PCI 24.5 (0.30) 13.5 (0.48) 20.9 (0.61) 27.0 (0.64) 34.3 (0.61) 
CABG 14.0 (0.24) 15.9 (0.52) 17.8 (0.57) 13.7 (0.49) 9.8 (0.38) 
Stent 13.3 (0.24) --- --- 17.9 (0.55) 30.5 (0.59) 
* Medication information for ACEI, Heparin, Lipid-lowering drugs, non-aspirin anti-platelets, and stents not collected during years  
    indicated by dashed lines (---) 
† Weighted number of definite or probable MI events 
‡ Chi-square test for independence with Taylor Series variance estimation significant for all variables at p <0.001 
§
 Percentages calculated using years in which data was collected for each therapy 
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Table S.2.1 Inverse probability of treatment weighed risk ratios for medical therapy use* and 30-day 
mortality† among hospitalized MI patients by propensity score (PS) analytic strategy: The ARIC 
community surveillance study (1987-2008). 
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Table S.2.2 Inverse probability of treatment weighed risk ratios for medical therapy use* and 90-day 
mortality† among hospitalized MI patients by propensity score (PS) analytic strategy: The ARIC 
community surveillance study (1987-2008). 
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Table S.2.3 Inverse probability of treatment weighed risk ratios for medical therapy use* and 365-day 
mortality† among hospitalized MI patients by propensity score (PS) analytic strategy: The ARIC 
community surveillance study (1987-2008). 
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Table S.2.4. Distribution of Covariates in Myocardial Infarction Patients Treated and Untreated with Calcium-Channel Blockers in 
Propensity Score Quintiles: The Atherosclerosis Risk in Communities Surveillance Study (1987-2008). 
 Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
Variable (%) Untreated Treated† Untreated Treated Untreated Treated Untreated Treated Untreated Treated 
Age (mean, SD)           
Male gender 78.1 74.9 63.8 57.1 64.1 66 70.1 74 51.6 54.6 
Race Classification           
Forsyth Black 6.8 8.6 13.6 16 9.6 9.4 10.5 8.9 12.7 11.3 
Forsyth White 20 17.6 32 26 30 27.6 25.5 31.2 30.8 38.5 
Jackson Black 15.5 18.1 15.8 18.1 10.3 10.7 9 7.7 13.5 8.8 
Jackson White 5.5 4.9 8.8 8.3 9.4 9.7 11.7 12 17.3 18.8 
Washington Whites 19.8 21.2 15.5 15.7 17.6 19.2 20.3 19.3 17.3 14.3 
Minnesota Whites 32.4 29.6 15.3 15.8 23.2 23.6 23 21 8.4 8.3 
Comorbidities           
Prior MI 19.1 23.9 31.5 32.2 35.3 35.6 35.3 33.5 42.9 42.4 
Diabetes 21 28 37.6 41.4 35.9 30.6 18.2 16.7 14.9 12.5 
Never Smoking 24.2 27.8 34.6 35.5 48.9 48.2 63.6 61.2 88 90.8 
Cardiogenic Shock 4.1 5.2 2.3 2 5 5.7 5.3 3.2 1 1.2 
CHF 26.3 37.4 27.3 34.5 31.4 33.3 33.7 30.8 41.8 25.7 
Cardiac Arrest 11.6 19.2 6.7 6.6 13.8 13.4 15.9 10.5 5.8 3.1 
STEMI 30.9 22.4 13.5 12.5 28.1 30.2 19.2 22.3 4.8 5.8 
Study Year           
1987-1991 0.0 0.0 0.3 0.4 8.5 11.7 38.7 38.2 74.4 75.7 
1992-1996 0.3 0.5 5.7 4.6 45.6 48.6 59.8 60.8 25.6 24.3 
1997-2001 25.5 28.3 50.9 52.9 39.1 35.3 1.5 1 0 0 
2002-2008 74.2 71.3 43.1 42.1 6.8 4.4 0 0 0 0 
Prior PCI 10.2 9.9 20.3 18.7 17.1 15.5 7.7 9.1 8.3 10.4 
Prior CABG 6.8 7.7 17.7 18.5 20.3 16.8 11.7 13.5 17.2 17.6 
*Quintiles of propensity score distribution from logistic regression models of medical therapy receipt and a standard set of covariates.  Non-overlap 
regions were eliminated and scores were trimmed by 5% on the right and left tails of the overlapping distribution 
†Treated at any point during hospitalization or at discharge 
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Table S.2.5 Distribution of Covariates in Myocardial Infarction Patients Treated and Untreated with Beta-Blockers in Propensity Score Quintiles*: 
The Atherosclerosis Risk in Communities Surveillance Study (1987-2008). 
 Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
Variable (%) Untreated Treated† Untreated Treated Untreated Treated Untreated Treated Untreated Treated 
Age (mean, SD)           
Male gender 58.4 60.1 63.2 63.7 64.6 65.3 69.8 69 66.9 69.2 
Race Classification           
Forsyth Black 13.2 11.6 9.3 12.4 11.9 10.8 9.3 8.9 9 9.3 
Forsyth White 22.9 23.9 24.3 22.8 32.5 31 33.1 31.9 28.1 31.4 
Jackson Black 15.4 14.1 14.2 13.5 13.6 14.9 9.4 11.8 9.8 9.1 
Jackson White 17.8 23.6 14.8 13 13.8 10.7 7.8 7.3 8 4.8 
Washington Whites 21.6 16.6 18 16.2 14.7 18.5 15.4 17.2 14 17.9 
Minnesota Whites 9.2 10.2 19.5 22.2 13.5 14.1 24.9 22.9 31.1 27.5 
Comorbidities           
Prior MI 42.3 42.4 38.2 35.3 31.7 31.4 25.5 29.4 27.4 29.4 
Diabetes 13.5 12.5 25.9 26.3 25.1 25.6 23.7 30.7 34.1 29.1 
Never Smoking 80.4 80.6 54.6 58.1 57.7 52.3 45.3 42 37.9 31.7 
Cardiogenic Shock 6.7 6.3 4.8 4.5 2.9 2.3 1.9 2.4 2.5 1.4 
CHF 63.9 51.1 39.2 38.6 29.3 31 20.3 24.9 9.1 12.3 
Cardiac Arrest 22.9 19.1 12 14.3 9.6 8.8 6.2 4.3 4.2 3.3 
STEMI 9.6 12 15 15.4 19.7 17.1 22.9 24.2 22.3 25.6 
Study Year           
1987-1991 66.3 66.2 28.6 29.2 31.4 26.2 13.9 9.2 0 0 
1992-1996 30.9 28.7 39.9 43 22.3 22.9 37.6 37.7 14.6 10.4 
1997-2001 2.8 5.1 30.3 24.6 33.3 34.5 19.3 19.9 34.8 49.6 
2002-2008 0 0 1.3 3.1 13 16.5 29.1 33.2 50.6 39.9 
Prior PCI 2.7 4 8 8.3 10 10.3 12.5 16.7 24.5 21.1 
Prior CABG 10.7 13.1 18.1 16.3 15.1 14.4 12.4 16.5 17.6 16 
*Quintiles of propensity score distribution from logistic regression models of medical therapy receipt and a standard set of covariates.  Non-
overlap regions were eliminated and scores were trimmed by 5% on the right and left tails of the overlapping distribution 
†Treated at any point during hospitalization or at discharge 
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Table S.2.6. Distribution of Covariates in Myocardial Infarction Patients Treated and Untreated with Aspirin in Propensity Score Quintiles*: The 
Atherosclerosis Risk in Communities Surveillance Study (1987-2008). 
 Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
Variable (%) Untreated Treated† Untreated Treated Untreated Treated Untreated Treated Untreated Treated 
Age (mean, SD)           
Male gender 51.3 54.4 57.3 60.6 59.4 56 68.8 65.6 70.8 72.4 
Race Classification           
Forsyth Black 10.2 11 13.4 10.5 10.7 13.1 18.9 16.7 11.2 10.3 
Forsyth White 14.1 13.7 22 21.5 14 16.7 26.7 25.7 39.2 35 
Jackson Black 17.7 16.2 15.3 16.6 28.4 23.6 9.7 14.5 3.9 6.1 
Jackson White 15.8 17.8 12.9 15.2 12.9 10.8 8.8 7.7 10.7 12 
Washington Whites           
Minnesota Whites 13.3 12 18.8 20 15.1 14.6 17.3 21.5 24.5 23.3 
Comorbidities           
Prior MI 38.4 38.5 35 39.9 30.8 32.8 33.5 35.6 57.9 41.4 
Diabetes 6.9 12 21 20.2 30.4 39.2 40.8 36 42.4 21.3 
Never Smoking 93.4 88.2 82 80.4 50.8 50.1 32.1 30.2 29.5 49.6 
Cardiogenic Shock 10.3 8.9 3 4.1 4.1 2.4 2.9 1.9 8.5 5.5 
CHF 65.4 59.8 36.7 40.1 50.2 49.8 30.2 27.5 20.3 23.3 
Cardiac Arrest 41.4 35.8 18.9 16.2 5 4.5 6.3 4.2 14.9 12.8 
STEMI 9.4 8.9 12 13.2 9.3 8.6 10.4 11.7 14.6 17.4 
Study Year           
1987-1991 --- --- --- --- --- --- --- --- --- --- 
1992-1996 10.1 11.8 25.6 28.1 9.3 37.6 22 21.3 15.2 13.3 
1997-2001 3.4 5.4 11.9 11.1 39.2 26.3 32.8 33.6 22.3 25.6 
2002-2008 3.3 6.3 12.2 10.4 28.8 29.6 41.8 41 45.5 24.3 
Prior PCI 1.5 1.2 4.9 5.1 23.9 6.1 11.1 16.2 35.2 27.3 
Prior CABG 4.8 3.9 11.4 16.4 12 11.4 22.4 19.8 36.1 31 
*Quintiles of propensity score distribution from logistic regression models of medical therapy receipt and a standard set of covariates.  Non-
overlap regions were eliminated and scores were trimmed by 5% on the right and left tails of the overlapping distribution 
†Treated at any point during hospitalization or at discharge 
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Table S.2.7. Distribution of Covariates in Myocardial Infarction Patients Treated and Untreated with ACE Inhibitors in Propensity Score 
Quintiles*: The Atherosclerosis Risk in Communities Surveillance Study (1987-2008). 
 Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
Variable (%) Untreated Treated† Untreated Treated Untreated Treated Untreated Treated Untreated Treated 
Age (mean, SD)           
Male gender 67.0 66.2 64.8 64.4 66.0 64.7 66.3 64.7 64.5 68.2 
Race Classification           
Forsyth Black 5.1 4.5 8.8 6.6 7.3 9.4 10.8 11 18.9 21.9 
Forsyth White 33.7 30.1 31.8 32.5 31.1 32.2 33 30.6 19.1 19 
Jackson Black 4.3 8.3 7.5 8.9 9.4 10.7 12.8 12.3 27.9 27.7 
Jackson White 13.4 18.6 10.8 12.6 11.1 7.1 8.2 7.3 5.3 4.2 
Washington Whites 22.9 18.3 20.6 19 20 19.1 13.2 16.6 9.6 9.7 
Minnesota Whites 30.5 20.3 20.4 20.4 21.1 21.5 21.9 22.2 19.1 17.5 
Comorbidities           
Prior MI 24.1 25.9 31.9 30.6 27.7 26.7 29.4 31.3 38 40 
Diabetes 9.6 21.3 22.5 25.9 22.5 25.5 37.6 33.2 62.1 60.2 
Never Smoking 51.4 45.1 39.9 42 35.7 40.5 27.1 29.6 28 23.8 
Cardiogenic Shock 3.1 3.4 3.3 4 2.6 2.9 3 2 2.8 2.8 
CHF 8.4 13.2 26.2 35 18.1 21.2 26.5 25 60 54.1 
Cardiac Arrest 12.4 16.7 13.2 12.9 7.9 8.3 8.9 6.4 5.5 3.1 
STEMI 14.9 13.8 26.1 20.1 14.1 15.6 20.3 21.1 20.1 24.7 
Study Year           
1987-1991           
1992-1996 98.1 98.1 66.1 60.4 15.2 17.9 3.1 4.4 0.4 0.4 
1997-2001 1.9 1.8 27.5 35 56.3 50.4 44.5 38.8 27.7 28.2 
2002-2008 0 0.1 6.4 4.6 28.5 31.7 52.4 56.8 72 71.4 
Prior PCI 10.2 7.8 12.3 11.5 16.2 13.1 15.5 20.2 20.6 23.3 
Prior CABG 12.8 14.5 13.2 15.8 15.6 15.2 16.0 16.0 20.8 19.4 
*Quintiles of propensity score distribution from logistic regression models of medical therapy receipt and a standard set of covariates.  
Non-overlap regions were eliminated and scores were trimmed by 5% on the right and left tails of the overlapping distribution 
†Treated at any point during hospitalization or at discharge 
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Table S.2.8. Distribution of Covariates in Myocardial Infarction Patients Treated and Untreated with Lipid-Lowering Medications in 
Propensity Score Quintiles*: The Atherosclerosis Risk in Communities Surveillance Study (1987-2008). 
 Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
Variable (%) Untreated Treated† Untreated Treated Untreated Treated Untreated Treated Untreated Treated 
Age (mean, SD)           
Male gender 52.5 49.3 59.9 61.2 68.2 70.6 74.6 67.6 71.7 74.6 
Race Classification           
Forsyth Black 14.2 10.1 12.1 15.0 13.6 12.3 6.4 7.7 9.9 12.2 
Forsyth White 19.2 24.3 25.1 24.0 29.3 29.3 35.5 33.8 36.0 31.8 
Jackson Black 27.6 27.2 19.7 21.1 11.1 12.4 12.0 11.5 11.5 8.7 
Jackson White 9.4 11.2 8.0 6.6 10.7 6.4 7.5 7.7 2.4 3.1 
Washington Whites 11.8 14.5 18.4 14.2 16.0 18.1 16.5 18.2 14.7 15.5 
Minnesota Whites 17.7 12.8 16.7 19.1 19.2 21.5 22.0 21.1 25.5 28.6 
Comorbidities           
Prior MI 17.7 19.7 26.6 29.1 33.8 37.1 34.6 25.8 27.8 19.2 
Diabetes 37.7 42.7 39.5 42.9 32.2 29.7 40.2 31.6 37.9 35.8 
Never Smoking 38.7 42.4 36.7 35.6 29.2 29.8 38.5 36.8 32.9 26.7 
Cardiogenic Shock 5.4 5.5 3.0 1.9 2.9 2.8 2.3 1.6 0.7 0.4 
CHF 64.2 55.8 30.9 33.3 21.0 18.8 13.8 20.0 7.6 5.0 
Cardiac Arrest 24.9 16.0 6.8 5.7 4.1 7.1 1.6 1.6 0.5 0.4 
STEMI 9.6 7.7 7.8 7.8 19.2 15.1 17.6 21.1 23.3 30.4 
Study Year           
1987-1991 --- --- --- --- --- --- --- --- --- --- 
1992-1996 --- --- --- --- --- --- --- --- --- --- 
1997-2001 60.8 61.3 22.8 27.7 59.4 49.6 41.0 30.6 14.0 7.1 
2002-2008 39.2 38.7 77.2 72.3 40.6 50.4 59.0 69.4 86.0 92.9 
Prior PCI 5.1 5.8 13.8 16.9 19.3 24.2 29.1 20.5 20.5 16.7 
Prior CABG 3.1 6.0 14.2 16.1 21.6 23.9 21.6 16.4 18.8 8.6 
*Quintiles of propensity score distribution from logistic regression models of medical therapy receipt and a standard set of covariates.  
Non-overlap regions were eliminated and scores were trimmed by 5% on the right and left tails of the overlapping distribution 
†Treated at any point during hospitalization or at discharge 
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Table S.2.9 Distribution of Covariates in Myocardial Infarction Patients Treated and Untreated with Non-Aspirin Anti-Platelets in Propensity 
Score Quintiles*: The Atherosclerosis Risk in Communities Surveillance Study (1987-2008). 
 Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
Variable (%) Untreated Treated† Untreated Treated Untreated Treated Untreated Treated Untreated Treated 
Age (mean, SD)           
Male gender 58.3 60.8 62.8 61.1 64.0 65.3 72.0 70.6 65.1 71.3 
Race Classification           
Forsyth Black 14.5 13.9 15.0 14.4 9.9 10.8 10.9 8.5 6.0 10.3 
Forsyth White 19.5 28.1 24.9 22.6 28.8 30.3 33.2 37.2 44.9 30.8 
Jackson Black 23.7 22.8 19.8 19.8 11.3 11.8 10.1 7.7 12.2 10.1 
Jackson White 10.5 7.2 7.1 7.3 9.7 10.5 5.4 6.5 3.6 5.8 
Washington Whites 16.1 13.7 14.6 19.3 19.8 17.4 18.3 15.4 15.5 16.7 
Minnesota Whites 15.7 14.4 18.6 16.5 20.6 19.3 22.1 24.7 17.8 26.4 
Comorbidities           
Prior MI 32.8 34.1 29.8 38.1 36.1 25.0 31.6 22.7 22.1 18.9 
Diabetes 43.8 45.8 38.2 42.7 39.7 34.2 28.1 22.9 34.0 30.0 
Never Smoking 38.1 35.1 34.7 32.9 29.3 32.8 30.5 30.7 27.9 34.3 
Cardiogenic Shock 2.6 3.1 2.3 2.3 4.7 3.3 2.6 2.9 1.1 2.0 
CHF 47.9 38.1 28.5 33.6 32.7 26.9 25.2 17.0 7.3 7.3 
Cardiac Arrest 11.7 13.7 6.7 5.1 8.7 7.9 4.7 5.3 3.4 4.1 
STEMI 9.0 5.9 7.0 8.7 17.1 16.9 31.5 31.8 17.7 20.8 
Study Year           
1987-1991 --- --- --- --- --- --- --- --- --- --- 
1992-1996 --- --- --- --- --- --- --- --- --- --- 
1997-2001 83.1 79.3 19.8 14.8 66.4 76.5 69.4 76.0 13.5 4.9 
2002-2008 16.9 20.7 80.2 85.2 33.6 23.5 30.6 24.0 86.5 95.1 
Prior PCI 7.9 8.6 20.4 23.9 25.1 19.0 15.3 15.4 18.5 16.0 
Prior CABG 15.7 17.2 22.1 24.5 18.8 16.0 13.0 9.9 9.5 9.9 
*Quintiles of propensity score distribution from logistic regression models of medical therapy receipt and a standard set of covariates.  
Non-overlap regions were eliminated and scores were trimmed by 5% on the right and left tails  
†Treated at any point during hospitalization or at discharge 
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Table S.2.10. Distribution of Covariates in Myocardial Infarction Patients Treated and Untreated with Heparin in Propensity Score 
Quintiles*: The Atherosclerosis Risk in Communities Surveillance Study (1987-2008). 
 Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
Variable (%) Untreated Treated† Untreated Treated Untreated Treated Untreated Treated Untreated Treated 
Age (mean, SD)           
Male gender 58.9 55.5 62.6 65.0 69.8 68.4 68.9 70.5 69.1 71.3 
Race Classification           
Forsyth Black 12.3 12.6 15.1 17.2 8.3 5.0 5.5 7.8 12.8 11.0 
Forsyth White 13.9 11.5 27.3 31.1 26.7 21.9 26.7 32.3 37.8 45.9 
Jackson Black 22.7 25.2 17.6 16.4 4.2 6.8 8.3 9.9 20.9 7.9 
Jackson White 12.0 13.4 8.8 7.7 5.9 7.8 9.1 11.1 12.3 7.6 
Washington Whites 7.2 4.4 18.9 19.6 25.1 18.1 12.6 12.0 7.0 22.2 
Minnesota Whites 31.9 32.9 12.2 8.1 29.6 40.3 37.8 26.8 9.1 5.4 
Comorbidities           
Prior MI 40.9 40.7 36.3 34.3 30.8 32.3 26.2 25.4 21.3 22.4 
Diabetes 27.8 34.4 43.0 40.4 33.8 32.8 22.0 21.9 28.9 27.2 
Never Smoking 61.9 61.2 26.3 25.6 51.4 43.5 44.5 40.4 18.9 18.4 
Cardiogenic Shock 1.7 2.0 2.8 2.5 4.1 5.0 1.8 2.8 3.6 2.2 
CHF 49.4 45.6 39.1 35.4 21.8 24.9 15.0 20.3 12.6 16.1 
Cardiac Arrest 12.8 12.8 10.7 9.3 7.5 9.1 5.6 7.4 5.6 5.3 
STEMI 4.3 7.2 8.6 10.2 21.8 20.4 24.9 22.5 35.1 32.3 
Study Year           
1987-1991 --- --- --- --- --- --- --- --- --- --- 
1992-1996 56.8 46.6 27.3 21.4 36.6 42.1 31.7 41.7 11.9 21.8 
1997-2001 18.9 21.3 37.9 35.7 30.7 28.5 23.8 26.9 34.8 38.0 
2002-2008 24.2 32.1 34.8 42.8 32.7 29.4 44.5 31.4 53.3 40.2 
Prior PCI 9.7 13.2 16.6 18.7 19.9 19.5 18.5 14.8 22.0 14.9 
Prior CABG 13.2 15.9 21.0 20.3 24.1 22.7 12.3 9.6 9.9 11.7 
*Quintiles of propensity score distribution from logistic regression models of medical therapy receipt and a standard set of covariates.  
Non-overlap regions were eliminated and scores were trimmed by 5% on the right and left tails of the overlapping distribution 
†Treated at any point during hospitalization or at discharge 
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Table S.2.11. Distribution of Covariates in Myocardial Infarction Patients Treated and Untreated with CABG in Propensity Score 
Quintiles*: The Atherosclerosis Risk in Communities Surveillance Study (1987-2008). 
 Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
Variable (%) Untreated Treated† Untreated Treated Untreated Treated Untreated Treated Untreated Treated 
Age (mean, SD)           
Male gender 45.1 38.6 65.5 68.3 60.9 62.1 75.4 75.7 92.5 93.2 
Race Classification           
Forsyth Black 28.9 28.3 13.9 13.1 2.6 3.3 0.0 0.0 0.0 0.0 
Forsyth White 4.2 5.2 16.9 16.6 26.4 24.9 41.7 41.6 65.2 68.9 
Jackson Black 34.2 30.9 12.5 11.3 2.1 2.1 0.0 0.0 0.0 0.0 
Jackson White 4.2 5.4 8.7 8.8 16.7 18.0 11.5 11.0 15.2 13.2 
Washington Whites 14.9 15.7 28.8 28.9 20.0 21.1 21.8 21.6 3.2 3.0 
Minnesota Whites 13.5 14.6 19.2 21.3 32.3 30.6 25.0 25.9 16.3 14.9 
Comorbidities           
Prior MI 32.2 28.6 37.0 43.6 32.3 33.4 30.6 29.2 29.6 27.8 
Diabetes 35.8 32.6 24.9 28.3 23.1 22.3 17.3 18.5 19.2 17.5 
Never Smoking 47.0 43.3 50.3 49.6 51.4 53.8 57.6 54.3 52.2 55.9 
Cardiogenic Shock 2.1 1.4 3.4 5.0 3.8 4.3 3.5 4.2 5.3 4.4 
CHF 37.1 35.3 31.9 35.4 29.4 34.2 27.6 24.6 20.6 18.6 
Cardiac Arrest 15.9 14.1 12.4 13.2 8.6 12.7 6.4 5.3 3.3 2.1 
STEMI 17.1 13.8 19.5 17.7 20.3 21.2 22.0 23.2 21.1 21.1 
Study Year           
1987-1991 16.0 13.5 25.5 25.5 25.6 25.0 31.6 29.6 27.3 30.4 
1992-1996 12.8 12.5 16.8 15.4 24.4 30.9 25.9 28.5 52.5 48.3 
1997-2001 20.3 22.8 27.3 25.6 24.7 23.5 29.5 28.1 20.0 21.1 
2002-2008 50.8 51.2 30.4 33.5 25.3 20.6 13.0 13.9 0.2 0.1 
Prior PCI 16.6 16.3 15.0 16.7 13.4 10.8 10.1 10.9 8.2 8.2 
Prior CABG 22.8 24.7 23.7 25.2 15.2 12.9 4.2 4.4 0.0 0.1 
*Quintiles of propensity score distribution from logistic regression models of medical therapy receipt and a standard set of covariates.  
Non-overlap regions were eliminated and scores were trimmed by 5% on the right and left tails of the overlapping distribution 
†Treated at any point during hospitalization or at discharge 
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Table S.2.12. Distribution of Covariates in Myocardial Infarction Patients Treated and Untreated with Angioplasty in Propensity Score 
Quintiles*: The Atherosclerosis Risk in Communities Surveillance Study (1987-2008). 
 Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
Variable (%) Untreated Treated† Untreated Treated Untreated Treated Untreated Treated Untreated Treated 
Age (mean, SD)           
Male gender 58.6 61.3 65.6 65.9 66.2 66.0 70.2 69.5 71.8 74.5 
Race Classification           
Forsyth Black 13.3 13.2 11.0 10.5 12.0 11.2 9.3 9.9 6.2 5.5 
Forsyth White 18.8 20.5 24.8 22.7 29.4 32.3 34.2 32.9 42.7 44.5 
Jackson Black 22.3 11.4 13.7 13.1 12.8 11.7 4.5 6.6 0.9 1.8 
Jackson White 14.3 17.3 14.4 17.8 9.8 8.1 10.6 8.9 4.4 3.7 
Washington Whites 20.5 21.9 20.9 17.9 17.5 18.5 17.9 17.7 9.3 7.8 
Minnesota Whites 11.0 15.7 15.2 18.0 18.4 18.2 23.5 23.9 36.6 36.7 
Comorbidities           
Prior MI 47.0 50.9 36.5 37.0 28.2 26.1 22.7 20.9 16.9 15.3 
Diabetes 31.9 30.4 26.6 29.8 27.9 23.8 23.5 23.9 16.4 16.0 
Never Smoking 64.2 65.6 58.4 59.6 49.1 48.6 39.7 38.8 35.5 33.4 
Cardiogenic Shock 4.3 6.4 3.9 4.3 3.1 3.6 2.8 2.5 3.6 2.6 
CHF 63.9 64.2 34.7 30.0 16.6 16.4 9.5 8.2 1.2 1.5 
Cardiac Arrest 15.6 17.8 10.4 8.7 8.1 7.0 5.9 4.8 3.8 5.4 
STEMI 7.0 5.9 11.3 11.4 16.9 15.2 24.5 22.1 39.3 47.8 
Study Year           
1987-1991 40.6 40.3 31.0 33.7 21.5 22.2 9.8 7.4 4.8 2.5 
1992-1996 27.1 27.5 29.0 27.7 29.0 31.9 25.0 25.3 17.1 14.7 
1997-2001 18.6 18.4 22.9 23.6 27.1 23.3 30.4 32.2 26.5 26.8 
2002-2008 13.7 13.8 17.0 15.0 22.4 22.6 34.8 35.0 51.6 55.9 
Prior PCI 6.5 12.1 9.2 13.8 14.4 13.8 17.6 17.5 23.6 20.2 
Prior CABG 19.3 25.2 18.1 22.8 14.8 12.8 14.1 12.7 8.5 4.8 
*Quintiles of propensity score distribution from logistic regression models of medical therapy receipt and a standard set of covariates.  
Non-overlap regions were eliminated and scores were trimmed by 5% on the right and left tails of the overlapping distribution 
†Treated at any point during hospitalization or at discharge 
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Table S.2.13. Distribution of Covariates in Myocardial Infarction Patients Treated and Untreated with IV t-PA in Propensity Score 
Quintiles*: The Atherosclerosis Risk in Communities Surveillance Study (1987-2008). 
 Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
Variable (%) Untreated Treated† Untreated Treated Untreated Treated Untreated Treated Untreated Treated 
Age (mean, SD)           
Male gender 59.1 66.0 66.5 66.5 73.3 72.4 74.0 71.8 73.9 75.6 
Race Classification           
Forsyth Black 8.6 11.1 1.9 3.2 2.5 1.9 7.9 7.6 1.6 0.4 
Forsyth White 32.7 29.8 36.0 35.7 27.8 32.3 20.5 19.0 31.5 32.5 
Jackson Black 16.8 16.7 10.2 8.5 4.8 4.7 6.2 8.4 8.4 5.9 
Jackson White 8.7 11.9 12.9 14.4 18.9 13.8 14.4 14.1 14.6 15.4 
Washington Whites 10.5 6.8 16.0 10.3 25.9 28.7 39.2 36.7 20.8 24.4 
Minnesota Whites 22.7 23.6 23.0 27.9 20.1 18.4 11.8 14.2 23.1 21.3 
Comorbidities           
Prior MI 44.8 47.1 29.4 32.1 20.0 14.3 19.8 20.0 11.1 10.1 
Diabetes 23.8 19.3 17.8 14.6 9.9 12.6 14.0 13.0 9.7 9.1 
Never Smoking 58.2 63.3 55.5 61.4 60.3 60.0 53.3 55.0 56.3 56.1 
Cardiogenic Shock 3.6 4.4 3.5 5.7 2.8 3.2 4.1 3.8 6.7 3.8 
CHF 40.5 35.3 22.1 22.7 14.2 10.4 17.9 22.1 16.2 12.3 
Cardiac Arrest 11.0 13.7 8.4 9.9 7.5 8.9 8.9 9.5 16.4 9.6 
STEMI 7.6 4.4 10.1 4.9 13.0 11.0 39.6 50.3 100.0 100.0 
Study Year           
1987-1991 32.4 38.0 30.4 39.9 39.0 41.1 32.8 30.0 35.6 35.4 
1992-1996 27.3 26.8 30.7 33.8 36.0 32.8 41.8 40.2 41.5 46.3 
1997-2001 33.4 31.7 30.0 23.6 17.9 20.4 23.8 27.3 22.9 18.3 
2002-2008 6.9 3.6 8.9 2.8 7.1 5.7 1.6 2.5 0.0 0.0 
Prior PCI 13.6 13.6 10.5 8.2 8.1 7.0 7.2 8.7 3.3 4.0 
Prior CABG 20.0 19.2 10.3 11.3 7.8 5.4 5.9 7.2 2.5 1.8 
*Quintiles of propensity score distribution from logistic regression models of medical therapy receipt and a standard set of 
covariates.  Non-overlap regions were eliminated and scores were trimmed by 5% on the right and left tails of the overlapping 
distribution 
†Treated at any point during hospitalization or at discharge 
 
1
2
0
 
121 
 
 
Table S.2.14. Distribution of Covariates in Myocardial Infarction Patients Treated and Untreated with Stents in Propensity Score 
Quintiles*: The Atherosclerosis Risk in Communities Surveillance Study (1987-2008). 
 Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
Variable (%) Untreated Treated† Untreated Treated Untreated Treated Untreated Treated Untreated Treated 
Age (mean, SD)           
Male gender 55.2 57.6 63.9 60.5 67.2 63.9 66.5 69.4 76.2 78.5 
Race Classification           
Forsyth Black 14.7 18.9 15.7 16.8 13.1 11.1 9.3 7.5 6.4 6.7 
Forsyth White 20.0 23.7 24.8 23.3 27.5 28.1 39.1 36.8 33.0 37.5 
Jackson Black 32.6 22.2 20.6 22.6 10.7 9.3 3.2 4.8 2.9 3.2 
Jackson White 9.2 6.5 8.3 9.1 9.7 8.3 5.8 5.7 2.6 3.8 
Washington Whites 13.3 15.0 17.2 15.4 19.0 20.6 16.0 19.6 19.2 13.2 
Minnesota Whites 10.2 13.6 13.4 12.9 20.0 22.6 26.6 25.7 36.0 35.5 
Comorbidities           
Prior MI 42.4 52.8 31.4 32.8 31.1 25.6 21.0 20.8 16.2 13.9 
Diabetes 56.7 55.2 44.0 43.8 30.5 32.9 27.0 23.0 16.5 16.2 
Never Smoking 38.4 37.5 31.8 34.2 32.3 28.6 30.6 32.6 32.3 32.6 
Cardiogenic Shock 2.3 5.3 3.0 4.1 2.3 1.9 3.0 2.1 2.5 1.9 
CHF 74.6 69.7 33.3 26.8 9.1 9.8 3.1 3.8 1.5 1.5 
Cardiac Arrest 12.3 12.5 7.0 6.1 4.8 5.0 5.3 4.7 3.2 4.7 
STEMI 2.2 2.0 6.6 5.9 7.0 6.5 14.3 15.6 50.0 52.9 
Study Year           
1987-1991 --- --- --- --- --- --- --- --- --- --- 
1992-1996 --- --- --- --- --- --- --- --- --- --- 
1997-2001 51.9 57.3 49.8 48.6 48.0 47.8 25.5 27.8 27.6 19.7 
2002-2008 48.1 42.7 50.2 51.4 52.0 52.2 74.5 72.2 72.4 80.3 
Prior PCI 15.6 29.1 16.2 18.8 20.1 16.7 26.6 21.3 17.6 18.8 
Prior CABG 24.1 33.5 19.8 20.5 15.9 16.7 15.9 10.0 3.5 4.4 
*Quintiles of propensity score distribution from logistic regression models of medical therapy receipt and a standard set of covariates.  
Non-overlap regions were eliminated and scores were trimmed by 5% on the right and left tails of the overlapping distribution 
†Treated at any point during hospitalization or at discharge 
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